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1. INTRODUCTION 
The World Health Organization (WHO) defines sexual health (SH) as a state of 
physical, emotional, mental and social well-being in relation to sexuality [1]. 
Sexual health (SH) is a core element to the physical and emotional health of 
individuals and a core element to the socioeconomic development of societies 
having profound short- and long-term consequences [2]. Some SH conse-
quences, namely trends in fertility during the second half of the past century, 
can influence the world as a whole. We are facing problems related to rapid 
population growth in the developing world and, the opposite problem, popu-
lation ageing as a result of low birth rates in many developed countries [3]. 
According to the WHO, the main domains of SH are: respect of sexual rights to 
have a safe and pleasurable sexual life; fertility regulation, e.g., avoiding unin-
tended pregnancy and childbearing; healthy childbearing; and maintenance of a 
healthy reproductive system [4]. The fifth domain – a sociocultural context – 
encompasses all the other domains (Figure 1). All domains of SH are closely 
linked, and improvements in one area tend to diminish problems in the other 
domains. 
 
 
Figure 1. The main domains of sexual and reproductive health. 
Source: Collumbien M, Busza J, Cleland J, Campbell O. Social science methods for research on 
sexual and reproductive health. Geneva: WHO; 2012:7. Published by permission of WHO. 
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SH is important for both men and women, but is more critical for women due to 
a combination of biological and social factors [5,6]. For women of reproductive 
age, 32% of the total global burden of premature death and disease is due to 
sexual and reproductive ill health [7]. This burden particularly largely reflects 
reproductive health and pregnancy where women’s health needs require special 
considerations and resources, but other aspects are also important. Factors in-
clude the unequal responsibility for contraception and infertility, burdens of 
sexually transmitted infections/human immune deficiency virus (STI/HIV), and 
hazards of sexual violence and intimate partner violence (IPV). According to 
Rebecca Cook et al, two main necessary conditions for good SH are success in 
achieving or preventing pregnancy and safety from STI/HIV [5]. Although un-
intended pregnancy is the focus of this research, it is important to acknowledge 
that all disparities in access to intended pregnancy play the same role [4,8]. 
The spirit of the definition of SH clearly indicates that it goes well beyond 
the absence of disease and emphasizes sexual rights as basic human rights. In 
European countries, such as Estonia, where maternal mortality and morbidity 
rates are low, abortion is legal and safe, and contraception is easily available, 
sexual ill-health burden and disparities in SH are related to a lack of information 
and knowledge, social inequality, gender-based inequality and violence [9]. 
SH is influenced by a complex interplay of biological, psychological, socio-
cultural, economic and political determinants which are difficult to measure. In 
2006, WHO, to monitor goals and targets of SH, created a list of the most 
important core reproductive health indictors [10]. While some data about SH 
are available routinely from countries, most indicators are based on population-
based surveys. Estonia has reliable data on the majority of core reproductive 
health indicators due to the population-based registers with national coverage – 
the Estonian Medical Birth Registry and Estonian Abortion Registry – which 
comprise a truly national data collection [11]. However, at the same time, there 
is a lack of reliable data about some other important SH indicators: use of contra-
ception and contraceptive services; IPV and its health consequences.  
 
The scope of this research is on women of childbearing age in Estonia within 
the two SH domains: firstly, avoiding unintended pregnancy with the focus on 
induced abortion and contraception; secondly, respect of sexual rights with the 
focus on IPV. 
 The Estonian Abortion Registry has been in operation since 1994 and is 
considered to provide valid and detailed data on abortions [11]. According to 
the Registry data, there was an apparently rapid decline in the number of 
induced abortions in Estonia during the last two decades. However, the abortion 
rate and proportion of repeat abortions – two to three times higher than that 
reported in most countries in the European Union (EU) – has attracted negative 
attention and raised questions about possible causes [12]. Therefore we aimed 
to describe the trends of induced abortion in Estonia from 1996 to 2011 with an 
emphasis on assessing sociodemographic characteristics and the use of contra-
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ceptive methods among women who underwent repeat abortions. The following 
research question was asked: “What are the sociodemographic characteristics 
and patterns of contraceptive use among women undergoing repeat abortions 
during the study period?” 
  
Induced abortion is mainly the result of non-use of contraception; incorrect, 
inconsistent use of contraception or contraceptive method failure. The second 
aim of the research was to assess contraceptive prevalence and patterns of con-
traception in order to discover the unmet need for family planning in Estonia. 
The research question was: “Which women are not served well by contraceptive 
methods in Estonia?”. Particular attention was paid to examining possible dis-
crepancies in contraceptive behaviour not only between the two main ethnic 
groups in Estonia, but also between groups of the same ethnic origin living in 
neighbouring countries – Estonia and Russia, namely, St. Petersburg. The two 
countries have different sociopolitical characteristics and public health plat-
forms allowing the evaluation of the effect of some contextual factors on contra-
ceptive behaviour, including the effect of health care services. We hypothesized 
that two ethnic groups – Estonians and Russians – might have different 
contraceptive patterns and factors influencing contraceptive behaviour.  
 
At different points in their lives, people may rely on different fertility regulation 
strategies and fertility intentions can change rapidly. Individuals’ perspectives 
on quality of health care are important because their views and experiences 
influence their satisfaction with care-related treatment adherence, likelihood of 
returning and their overall health outcomes [13]. The changes in the health care 
system, addition of new institutions (such as youth friendly clinics and the 
family doctor system) and provider roles (such as family doctors, family nurses 
and midwives) during the recent decades in Estonia has made it necessary to 
define their roles in the provision of contraceptive counselling. The third 
research question was: “Which health care institutions have been visited, which 
institutions are preferred and how satisfied are people with contraceptive 
counselling in Estonia?” 
 
Sexual relationships have a fundamental influence on SH outcomes and re-
productive choices. IPV is behaviour within an intimate relationship that causes 
physical, sexual or psychological harm [14]. There is strong evidence that IPV 
is consistently associated with increased risk for a number of adverse sexual and 
other health outcomes among those who have experienced IPV [15–23]. In 
addition to its human costs, IPV places an enormous economic burden on 
societies in terms of lost productivity and increased use of social and health 
services [14,22].  
In Estonia, as in other East European countries, IPV has only recently been 
acknowledged and discussed publicly [24,25]. At the same time, the general 
population and governmental structures still consider IPV to be a private issue. 
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Estonian criminal law does not address most of the specifics of domestic violence 
[24,26], there are no strategies or guidelines in place for the health care system 
or providers on how to best manage cases of IPV. Given that at the country 
level, there is no systemic data collection and only scarce research data exist 
about IPV, we posed the fourth research question: “How prevalent is IPV in 
Estonia and how does IPV influence SH outcomes?”. 
 
In conclusion, the aim of this research is to fill the knowledge gap on women of 
childbearing age in Estonia within the SH domains of respect of sexual rights to 
have a safe, pleasurable sexual life and fertility regulation by specifically focus-
ing on unintended pregnancy (induced abortion and contraception) and IPV. 
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2. ESTONIAN CONTEXT 
2.1. Geography, economics and sociodemography 
Estonia is one of the smallest countries in the European Union with a territory 
of 45 200 sq km and a population of 1.32 million people, 45.6% of whom are of 
reproductive age (15–49-years) [27]. Since the restoration of independence in 
1991, Estonia has developed into a fully functioning democracy and adopted 
liberal policies in its transition to a market economy. In 2013, the minimum 
wage expressed in purchasing power standards was 411 EUR per month (the 
fourth lowest in the EU) [28]. In human development, Estonia ranked 32nd 
among 174 countries in 2013 [29]. 
Almost two thirds of the population of Estonia are urban. The population 
consists of two large ethnic groups, namely Estonians (69.9%) and Russians 
(25.2%) according to the latest census (as of 31 December 2011) [27]. Estonia 
has one of the highest proportions of ethnic minorities in the population in the 
EU accounting for one-third of the total population. Society is segregated 
according to ethnicity across a number of dimensions: language, work and geo-
graphy – due to reasons rooted in the Soviet occupation of Estonia from 1940 to 
1991 [30,31]. Data has shown that ethnic Russians have, on average, a lower 
health status than members of the majority ethnic group of Estonians [32] 
The total fertility rate (TFR) is 1.57 lifetime births per woman. There was a 
drop in the fertility rate from 1990 until 1998 and the rate has been falling again 
since 2011. In the intervening period, the TFR increased. In 2013, the annual 
number of live births was 13,984, i.e. 46.7 per 1,000 women of childbearing age 
[11].  
 
2.2. Health system 
In 2011, Estonia spent 5.9% of its gross domestic product on health (equal to 
US$ 1,010 per capita) compared to the EU average of 9.6% [33], however, the 
proportion of publicly-funded health expenditure is relatively high [34]. The 
Estonian health system is based on compulsory, solidarity-based insurance and 
universal access to health services. A quite stable proportion, around 95% of the 
population, is covered by insurance [34]. Contributions to insurance are related 
to employment, but the share of non-contributing individuals (children, pen-
sioners) represents almost half of the insured; antenatal and obstetric care are 
covered by insurance. Primary health care is provided by family doctors, who 
are “gatekeepers” for secondary care, although gynaecologists can be accessed 
directly.  
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2.3. Gender equality 
The Gender Equality Act was first adopted in Estonia in 2004. In Estonia, the 
employment rate of women is one of the highest in the EU (70.6%) [28]. Part-
time work is not common for either women or men – in 2010, 10% of women in 
the prime working age (25–49) worked part-time compared to the EU average 
of 29% [28]. Women are disproportionately represented among high school 
graduates – 60% of graduates from institutions of higher education are women 
and there are 148 women with higher education for every 100 men with the 
same level of education. In parallel with the high employment rate and high 
graduate education levels among Estonian women, there is the largest pay gap 
(30%) between women and men in the EU [28]. At the same time, the life 
expectancy gap between the sexes, about 10 years, is one of the highest in the 
EU (in 2013 it was 69.4 years in males, 79.2 years in females) [27,28]. 
 
 2.4. Sexual and reproductive health 
Family planning and sexuality issues have become the focus of public debate 
since the 1990s. Over the past two decades, Estonia has taken SH as a human 
right rather than taking a moralistic approach to social problems related to 
sexual behaviour, however, traditional discourse and understanding of sexuality, 
gender dynamics and the family persist. 
The State Sexual and Reproductive Health (SRH) programme was imple-
mented from 2000–2009. Since then, the topics of the SRH domain are covered 
by the State Public Health Development Plan 2009–2020 and the State Strategy 
on HIV/AIDS 2006–2015.  
After the collapse of the Soviet Union in the early 1990s, the growth in in-
formal economies, including drugs and the sex trade, dramatically escalated the 
incidence of STI/HIV [35]. Despite the welcome decline of HIV/STI, Estonian 
HIV rates remain higher than those in other European countries – in 2013, HIV 
prevalence in the 15–49 years age group in Estonia was 1.3% (1%−1.6%) [36]. 
Most SRH indicators, collected by EMBR and EAR, have improved signi-
ficantly over the last 20 years. For example, perinatal mortality (number of peri-
natal deaths per 1000 births) decreased from 20.1 in 1992 to 3.7 in 2013 and is 
among the lowest in the EU [37]. Estonia has experienced a remarkable de-
crease in rates of abortion and teenage pregnancy since 2001 which have 
occurred in parallel with the implementation of school-based sex education and 
the establishment of youth SRH services. Sexuality education has been a man-
datory part of the Estonian school curriculum since 1996. The country has 
embarked on a radical transformation of its SH services; specific and successful 
efforts to reach adolescents and young people have been made [38,39]. In 1991, 
the first youth-friendly clinic (YFC) was established to address sexual health 
issues of young people; by 2015, the number of such clinics had increased to 
20. Overall, it is believed that these developments have led to the positive 
changes in many SH outcomes [38,40,41]. 
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3. REVIEW OF LITERATURE 
3.1. Sexual health  
The WHO working definition about SH, substantially recreated from the defini-
tion of “health” by WHO in 1948, is:  
 
”Sexual health a state of physical, emotional, mental and social well-being in 
relation to sexuality; it is not merely the absence of disease, dysfunction or in-
firmity. Sexual health requires a positive, respectful approach to sexuality and 
sexual relationships and the possibility of having pleasurable and safe sexual 
experiences, free of coercion, discrimination and violence. For sexual health to 
be attained and maintained, the sexual rights of all persons must be respected, 
protected and fulfilled” [1].  
 
Firstly, this definition accentuates the positive approach to SH, which leads a 
shift from treating sexual ill-health to promoting sexual well-being. Secondly, it 
affirms the need to ensure protection and exercise of the individual’s sexual 
rights – human rights including “right to bodily integrity; consensual sexual 
relationships; access to sexual health services; to decide freely the number, 
spacing, and timing of their children; and the ability to pursue satisfying, safe 
and pleasurable sexual life” [1]. This approach to SRH has been adopted at the 
international scene since 1994 when the International Conference on Population 
and Development (ICPD) in Cairo took place. However, the Programme of 
Action of the IPCD subsumed sexual health into reproductive health [42]. Since 
then, there have been important developments in how human sexuality and 
sexual behaviour are understood, particularly in relation to the HIV epidemic, 
gender-based violence, unsafe abortion, and other health and social factors that 
affect SH. These understandings aimed to review how SRH is defined and pro-
moted. It has been widely recognized by international experts that the concept 
of “sexual health” is much broader – rather than being a component of repro-
ductive health, SH is a necessary condition for the achievement of reproductive 
health and remains relevant throughout the life-course and for diverse 
sexualities [1,43,44]. 
 
3.1.1. Sexual health determinants 
Similarly with other areas of health, SH is influenced by a complex interplay of 
biological, psychological and social determinants. Even not all aspects of SH 
have the same set of determinants and their influence variate in different coun-
tries and different population subgroups; there are some common determinants 
that impact upon every aspect of SH [2,5,44]. SH is deep-rooted in a biological 
dimension – sex and genetics. In every country, people’s ability to make deci-
sions about their sexual life occurs in a different context with different personal 
resources (education, marital status, ethnicity, income, employment etc) and the 
16 
capacity to use the resource. Unsatisfactory SH may be the result of lack of 
information and skills or clashing goals – the dynamics and complexity of 
sexual relationships have a fundamental influence on SH outcomes and repro-
ductive choices. However, SH is a politically and socially highly contested area 
of health. Even certain human sexual behaviours and relationship qualities 
create, enhance and perpetuate SH outcomes, individual choices are influenced 
by a range of sociocultural, religious, legal, political and economic factors, over 
some of which the individual has little or no control [2,4,5,44]. Political and 
legislative environment, the level of a country’s wealth and the distribution of 
power and wealth may promote or limit individual’s ability to adopt healthy 
behaviour. For good SH, the two necessary pre-conditions are access to sexu-
ality education and health care services [2,4,5,44]. Additionally, the dominant 
sexual ideology, accepted by a society, is one of the major determinants of SH 
[4,44]. Sexual ideology means values and norms, set by the community and 
larger cultural environment, which affect the sexuality and govern the sexual 
behaviour of individuals and couples. Health-compromising practices often 
reflect these norms, e.g., IPV, sexual violence, social exclusion as a result of 
sexual identity or infertility. 
 
3.1.2. Sexual health indicators 
SH as a complex and multi-dimensional concept is difficult to measure. A 
shortage of reliable data represents a barrier towards monitoring SH and use of 
indicators represents an attempt to fill in the gap in available data. According to 
WHO, indicators are “markers of health status, service provision or resource 
availability and are designed to enable the monitoring of goals or targets” [10]. 
Monitoring is a process of comparison, across populations, geographical areas 
or time, to highlight differences or to detect changes over time [10].  
 
WHO classified SH indicators into the following four categories: 
1) policy and social indicators; 
2) access to services: availability, information and demand, quality; 
3) use of services; and 
4) outcome and impact indicators [2]. 
 
While some indicators are available routinely from countries which have vital 
registration and health information systems, most indicators are based on popu-
lation-based surveys. 
After the ICPD, a number of international organisations identified a list of 17 
indicators for global monitoring and evaluation of reproductive health goals and 
targets [10]. Due to relative ease of measurement, most of the 17 indicators 
were outcome measures and focused on negative outcomes. The shift in the 
meaning of sexuality and SH has created a demand for tools with which to 
measure SH better. The recent new indicators recommended by WHO were 
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designed to complement and expand upon the 17 reproductive health indicators 
by including the concept of universal access to reproductive health and different 
aspects of SH, including sexual violence [2]. Some of the indicators are 
measures of health status (outcome or impact indicators) while others are inten-
ded to capture a process or a structure. The indicators proposed were grouped 
under the five core elements of SH:  
1) improving antenatal, delivery, postpartum and newborn care;  
2) providing high-quality services for family planning, including infertility 
services  
3) eliminating unsafe abortion;  
4) combating STI/HIV, reproductive tract infections, cervical cancer and other 
gynaecological morbidities;  
5) promoting SH [2].  
 
Furthermore, the global indicators need to be modified according to local con-
texts – not all indicators are applicable to every country situation. In 2001, un-
der the auspices of the European Union (EU) health monitoring programme, a 
project REPROSTAT was undertaken to develop a comprehensive set of SRH 
indicators for EU Member States. A final set of 13 core indicators for EU coun-
tries was developed, as well as a list of indicators that needed further develop-
ment [45].  
 
 
 3.2. Induced abortion 
The root of induced abortion is unintended pregnancy. According to WHO, an 
unintended pregnancy is an unplanned pregnancy which is either unwanted (that 
is, the woman did not want to conceive or did not want any more pregnancies) 
or mistimed (that is, the woman wanted to get pregnant, but not within the next 
two years) [46].  
 
3.2.1. Induced abortion and health 
Among the 208 million women estimated to become pregnant each year world-
wide, 59% (123 million) experience an intended pregnancy leading to a birth or 
miscarriage, the remaining 41% (85 million) of pregnancies are unintended [47]. 
A third of pregnancies are estimated to be unintended in France [48], two in 
five in Spain [49], and between a third and half in the USA [50,51]. However, 
this dichotomous division has been criticized as many people have ambivalent 
feelings about pregnancy. One of six pregnancies was unintended, between a 
quarter and a third were ambivalent, and over half were planned in a large popu-
lation based study NATSAL from Great Britian [52]. In Estonia, a study among 
pregnant women who had chosen childbirth indicated that 22.7% of pregnancies 
were unplanned [53]. 
5
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Induced abortion has been documented throughout the recorded history as 
debates about birth control methods [54]. In earlier times, all abortions were 
unsafe with enormous risks on women’s lives. Advances in medicine and, in 
particular, the human rights recognition, made abortion a safe medical proce-
dure and complications from abortion are generally very low [55]. Legal, regu-
latory, policy and health care contexts concerning abortion vary from country to 
country, have no effect on a woman’s need for an abortion, but may dramati-
cally affect her access to safe abortion. Highly restrictive abortion laws are 
associated with higher abortion rates. For example, in 2008, the abortion rate 
was 32 per 1,000 women of fertile age in Latin America and 29 per 1,000 in 
Africa – in the regions where abortion is illegal in the majority of countries. In 
Western Europe, where abortion is generally permitted on broad grounds, the 
according rate was 12 per 1,000 [56]. Each year, an estimated 22 million abor-
tions continue to be unsafe, resulting in the death of an estimated 47,000 women 
and causing 5 million women to suffer from a disability as a result of compli-
cations due to unsafe abortion [55]. Almost every one of these deaths and dis-
abilities could have been prevented through access to sexuality education, contra-
ception, and safe induced abortion. 
In developed countries unintended pregnancy is strongly associated with 
health-related factors (smoking, drug use, depression), as well as aspects of 
sexual behaviour (early and risky sexual debut, receipt of sexual education from 
sources other than school, higher frequency of recent sex, and many sexual 
partners) [52,57].  
 
3.2.2. Reliability of abortion data 
Data about abortions are obtained from different sources. In surveys abortion 
incidence is generally underestimated because a large proportion of women do 
not report their abortions, which occurs to a greater extent in countries with 
restrictive laws than in those with liberal laws [56]. Countries with liberal abor-
tion laws have usually some mechanism for regular collection of national statis-
tics. However, even then, statistics on abortion incidence are largely prone to 
misreporting for many reasons: potential sources of error include missing pri-
vate sector abortions; inclusion of spontaneous abortions; induced abortions 
registered as miscarriages, undercounting of medical abortions or the so-called 
“menstruation regulation” procedure, the inclusion or exclusion of abortions of 
non-residents and migrants in the national statistics [56, 12, 58]. Part el al., ana-
lysing REPROSTAT data about teenage pregnancy rates in Europe, concluded 
that to interpret data about abortions in EU, it should take into consideration 
other factors influencing abortion rates, including birth rates and CPR in a 
particular country [41]. One of the conclusions of the REPROSTAT project was 
that more consistent reporting of abortion is needed in the EU [12]. 
One example is Russia, where abortion level has been exceptionally high for 
several decades, yet the last two decades experienced a considerable decline 
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according to official statistics. There are advocates that statistics on abortion in 
Russia are a true reflection of the situation and the observed declining trend in 
abortion is a real one [59], but also a concern that this favourable change could 
be largely due to a deterioration of statistical registration already in the 1990s 
[60]. Last assessment is strongly supported by the fact that at the same time the 
recent trends in modern contraceptive prevalence show a rise in all countries, 
except in Russia, where the upward movement appears to level off after 1996 
[61–63]. 
 
3.2.3. Induced abortion trends worldwide 
A notable worldwide decline of induced abortion, mainly attributed by a decline 
in Europe, from 35 abortions per 1,000 women in 1995 to 29 in 2003, was re-
placed by a fairly stable period in 2003–2008: 28 abortions occurred for every 
1,000 women aged 15–44 years in 2008 [56]. In 2008, the estimated rate was 24 
in the developed world and 29 in the developing world. The decline has been 
largely due to a fall in the rate of safe abortion, while since 2000, the rate of 
unsafe abortion has remained relatively constant with about 14 per 1000 women 
aged 15–44 years [47]. Worldwide, 49% of abortions were unsafe in 2008, up 
from 44% in 1995 [56]. The lowest rates of induced abortion are in Europe. The 
results indicate persistent and significant, up to four-fold, differences in the 
rates of termination of pregnancy among the EU Member States [12]. The 24 
EU Member States report annually approximately 1.2 million abortions, repre-
senting 10.3 abortions per 1,000 women aged 15–49 years. The lowest figures 
were reported in Germany, Greece, Belgium, the Netherlands and Portugal (6–
7.5 per 1,000 women in fertile age). Estonia, Bulgaria, Romania had the highest 
rate of 20 or more per 1,000. 
 
3.2.4. Induced abortion in Estonia 
Abortion has been legalized since 1955 and it happened before any effective 
modern contraception became available. In all former Soviet republics, Estonia 
among them, the majority of women relied on non-effective means of contra-
ception, which resulted in the highest incidence of induced abortions in the 
world [64–66]. This led to what some scholars call an “abortion culture”, 
whereby women relied primarily on abortion as a family planning method 
[67,68]. However, abortion was never a matter of choice in the Soviet Union 
because there were no other effective choices [66,67]. Experts debated about 
serious dangers of abortion and, at the same time, about serious dangers of hor-
monal contraception [64,69]. Since abortion was provided in health care system, 
it was a safe medical procedure, but abortion patients were sometimes treated 
not respectfully. 
In Estonia, abortion is regulated by the Termination of Pregnancy and Steri-
lisation Act adopted by the Parlament of Estonia (Riigikogu) at the end of 1998. 
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The level of legislation appears to correlate with abortion accessibility during 
this long period of time. Women have been legally allowed to request an abor-
tion up until the 12th week of pregnancy. Termination on medical grounds, in-
cluding termination in females under 15 years and over 45 years of age, is 
allowed until the 22nd week of pregnancy. The only change in legislation – the 
parental consent for minors under 18 years has been required since 2009 – was 
cancelled after heavy debates on 2nd of March 2015. All abortions are performed 
in health care institutions, holding a license for that procedure, via health in-
surance schemes for which some of the costs (EUR 35–44) are met by the 
patient. Medical abortion was introduced in 2005 and in 2013, half of termi-
nations were medical [11]. 
After regaining independence from the Soviet Union in 1991, Estonia expe-
rienced an apparent rapid decline in the number of induced abortions. Never-
theless, REPROSTAT data have shown a 2.5 times higher abortion rate in 
Estonia than the reported total average in the European Union (25.1 vs 10.3, 
respectively in 2008) [12]. Moreover, the percentage of repeat abortions did not 
show the same rapid decline and represented a significant proportion of all 
induced abortions – two out of three abortions in Estonia were obtained by 
women who had had at least one before [11]. The number of repeat abortions in 
Estonia is twice as high as that in countries like Sweden, Finland, England, and 
Wales [70–72].  
Statistical data on abortions have been routinely collected by the Estonian 
Abortion Registry (EAR) since 1996 [11]. Before EAR was established, only 
aggregate data from medical institutions were collected by Estonian Medical 
Statistics Bureau. The reliable data collection conducted by the EAR may partly 
explain why the abortion rate in Estonia has been reported one of the highest in EU.  
In the contemporary Estonia, some religious and moralistic dilemmas around 
abortion issue have been periodically raised with attempts to undermine abor-
tion rights. It is of paramount importance to have recent and evidence-based 
knowledge about such sensitive public health issues in order to try and find 
practical solutions for avoiding unintended pregnancies. 
 
 
3.3. Contraception 
The determinants that affected the abortion rate included a desire for smaller 
families, a rise in women’s age at marriage and first childbirth, an increased 
prevalence of sexual activity among unmarried women, and a growing partici-
pation of women in the labour market [73]. However, the main contributor to 
the decrease in the incidence and prevalence of induced abortion worldwide is 
an increased use of modern contraception [73].  
Contraception is one of the most visible and demanding part of a woman’s 
SRH concern as far they are exposed to the risk of unintended pregnancy over 
much of their lives. 
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3.3.1. Contraception as a human right,  
developmental and health issue 
Over the past 50 years, access to contraception has moved from being an im-
portant goal of SRH programmes to becoming a basic human right [74,75]. The 
most important result of the increased access to contraception is that it has 
helped to liberate women and promote gender equality – the principles of 
human rights have enabled millions of women to freely choose the timing and 
number of their children. Recently, WHO published recommendations 
especially to point at human rights protection and promotion in the context of 
contraceptive information and services [76]. 
Introduction of modern contraceptive methods is responsible for most of the 
global fertility decline over the last 50 years – fallen by more than 50% since 
1950 [77]. The other economic consequences of contraception are associated 
with women’s employment and an increase in their earnings, healthier and better 
educated children, and an increased proportion of people of working age [78]. 
The single greatest health benefit of contraception comes from their intended 
action since the prevention of unintended pregnancies results in a subsequent 
decrease in maternal and infant mortality and morbidity. The latest estimates are 
that 222 million women worldwide have an unmet need for contraception and 
the need is greatest where the risks of maternal mortality are highest and 
abortion is illegal or unsafe [79]. The number of women who die every year as a 
result of pregnancy or delivery is estimated to be about 300,000 [80,81]. Many 
of these deaths are avoidable – two independent analyses using different 
methods came to the same conclusion: elimination of the unmet need for 
contraception in developing countries would reduce maternal deaths by about 
30% preventing 54 million unintended pregnancies and 79,000 maternal deaths 
worldwide [79,82].  
In addition to the utmost public health perspective, access to and use of con-
traception also contributes to individuals being able to take control over their 
own body and sexuality, thus helping them to achieve a safe and satisfying 
sexual life and health [83].  
 
3.3.2. Contraceptive methods efficacy,  
effectiveness and measurements 
During the last two decades, there have been significant advances in the develop-
ment of contraceptive technologies, including transitions from high-dose to low-
dose combined hormonal contraceptives; from synthetic oestrogen to natural 
oestrogen; development of new progestogens and delivery methods of hormones 
(hormone-releasing intrauterine system, skin patch, vaginal ring, implants); less 
invasive methods for sterilization and new emergency contraceptive agents have 
been introduced. Since an ideal contraceptive method is missing, no single 
contraceptive method serves the needs of everybody. A variety of methods is 
overwhelmingly important to meet different needs and all, often unequal, 
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opportunities. Contraceptive use overall is greater when more methods are 
available [84].  
In family planning programmes contraceptive methods are usually divided as 
modern (clinic and supply methods) and traditional (non-supply) methods [10]. 
Modern methods include female and male sterilization, copper-releasing in-
trauterine device (IUD), hormone-releasing intrauterine system (IUS), hormonal 
methods (pill, patch and ring, injectable, implant), condom and vaginal barrier 
methods (diaphragm, cervical cap and spermicidal agents); traditional methods 
include rhythm method, withdrawal, abstinence and lactational amenorrhoea 
[10]. Although, some traditional methods, like breastfeeding, could be reliable 
[85], and modern methods, like spermicides, unreliable; original concept of 
modern contraceptive methods is coming from the most important feature of 
contraceptive method – its efficacy.  
Contraceptive efficacy is assessed by the rate of unintended pregnancies dur-
ing a specified time of exposure. Recently published systematic review about 
published clinical trials presents the hierarchy in descending order of contra-
ceptive efficacy as follows: female sterilisation/long-acting hormonal contra-
ceptives; Cu-IUDs/short-acting hormonal contraceptives; and barrier methods/ 
natural methods [86]. Translating efficacy (how well the product works in a 
clinical trial) results into practice (how well the product works in actual 
practice), “perfect use” and “typical use” efficacy rates are often presented. 
Effectiveness of contraceptive methods – their use under typical conditions – is 
categorized into three tiers ranging from the most effective (implants, IUDs, 
sterilisation) to the least effective methods (traditional methods and barrier 
methods, including male/female condoms) [87]. Effectiveness of every method 
is dependent on its correct and consistent use and the frequency of intercourse 
[88] – half of all unintended pregnancies in US occur among contraceptive users; 
only one in ten result from method failure and nine in ten from inconsistent or 
incorrect method use [89]. 
Among all the reasons why women choose particular contraceptives, method 
effectiveness ranks one of the most important. [90]. However, from user per-
spective there could be other qualities which have at least the same importance 
as effectiveness. The main concerns are side-effects or health concerns – in some 
countries, 30–50% of women discontinue use of hormonal methods within the 
first year of use because of side-effects or health concerns [91]. Other players in 
decision-making process might be partner-indipendency, user-indipendency, 
coitus-indipendency, quick fertility reversibility. According to Marcia Meldrum, 
Christopher Tietze wrote already in the 1950s that “…any contraceptive 
approach succeeds only if it is “use-effective” – one which individual women 
(and men) find appropriate for use within their own lives”[92]. In addition to 
effectiveness in preventing pregnancy, some contraceptives also have sub-
stantial non-contraceptive health benefits. Condoms prevent STI/HIV. Hormonal 
methods exert a beneficial effect on many aspects of menstrual bleeding, re-
ducing the risk of iron deficiency anaemia; preventing ovarian, endometrial and 
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colorectal cancer, functional ovarian cysts, pelvic inflammatory disease (PID), 
ectopic pregnancy, benign breast disease and; these are effective to alleviate 
symptoms caused by endometriosis and fibromyoma. Combined hormonal 
methods have the potential to reduce symptoms related to excess of androgens 
[93]. More than half of pill users, 58% rely on the method at least in part for 
purposes other than pregnancy prevention; 14% of pill users rely on the method 
for only non-contraceptive purposes [94].  
Contraceptive methods for men are limited to male condoms and steri-
lization (vasectomy). 
 
Contraceptive prevalence rate (CPR) and the unmet need for contraception (or 
the unmet need for family planning) are two key indicators for measuring 
improvements in SH. Contraceptive prevalence means the proportion of women 
in reproductive age (15–49) currently using a contraceptive method divided by 
number of women of reproductive age at risk of pregnancy (sexually active, not 
infecund, not pregnant, not amenorrhoeic) at the same point in time [10]. The 
unmet need for contraception concerns women who are at risk of pregnancy but 
do not use contraception. Broder definition of the unmet need for contraception 
includes women who use contraceptive methods with limited efficacy; women 
with unwanted pregnancies; and women with related reproductive health prob-
lems like infertility caused by STI/HIV [95,96]. It is even argued that if a 
woman is using a method that she does not like, it should be considered as 
having an unmet need [74]. The definition itself is not necessarily a problem 
until the data are misinterpreted. In countries, like Estonia, where traditional 
contraceptive methods are still widely used, the difference between levels of 
unmet need calculated using the conventional or expanded formulation may be 
considerable. 
 
Data from contraceptive prevalence could be obtained from several sources. 
However, a population-based sample surveys provide the most comprehensive 
data on contraceptive behaviour [10]. Differences in design and questions of 
survey can affect the comparability of the data. Since there is no consistent defi-
nition across data sources of what is meant by “currently using” a method of 
contraception, for measuring CPR, it should be taken into consideration what 
time period was concerned. Most surveys ask about use “now” or within the 
past month, although some specify other time periods. As there are usually diffi-
culties to obtain data on how correctly and consistently the methods are used, 
one option is to chose the contraceptive method used during the last intercourse 
as an outcome measure. The limitation is that measures of contraceptive use at 
one point in time do not take into account its changing nature. The precentage 
of contraceptive methods is usually higher than 100% as some people use more 
than one method concurrently. The list of indicators about contraception was 
recently expanded – indicators measuring different aspects of access to and 
satisfaction with contraceptive services has been added [76]. 
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3.3.3. Factors influencing contraceptive behaviour 
In developed countries where all modern contaceptive methods are available, 
only few practise unprotected sex. In comparative population representative 
samples, 7.4% of women in US [97], 5% in Australia [98], 9% in Canada [99], 
and 2.7% in France [48] did not use any contraceptive method during their last 
intercourse. This indicates that the availability of and access to contraception is 
not sufficient – even in countries where modern contraception is readily avail-
able, there are women and couples who do not want to become pregnant but still 
do not use contraception.  
According to the studies, explanations, why women who wish to avoid preg-
nancy do not use contraception, largely fall into four categories: contraceptive 
method-related factors; user-related factors; partner-related factors; and cost 
[50,100,101]. From user-related perspective, different patterns of contraception 
use result from user sociodemographic background. Women with a low socio-
economic status and educational level and belonging to ethnic minorities have 
shown less effective use of contraception. [8,51,52,89,97,102–105]. A review 
on the research from 1995 through 2005 aimed to determine the reasons for 
contraceptive non-use among women who are at risk of unintended pregnancy, 
identified multiple associated factors, including contraceptive side effects, cost, 
lack of access, low perceived risk, lack of planning, negative attitudes, ambi-
valence about pregnancy, perceived negative influences from partner and friends, 
dissatisfaction with health care providers, and forced sex [102]. A review of 45 
publications since 2005 on factors associated with unprotected sex found that it 
has consistently been associated with increasing age, being married, recent 
experience of IPV, contraceptive side effects, and infrequent sexual intercourse 
[106]. However, differing patterns of contraceptive use across regions may not 
always reflect women’s personal preferences and sexual behaviours as much as 
contextual factors – sociopolitical decisions, the range of methods offered, 
access to health care services, the attitudes of medical professionals and cultural 
diversities [8,50,89,97,101,106]. Further, sociocultural environment, e.g., sexual 
ideology, contributes to and shapes individual choices and behaviours [4,81]. 
For example, Kulczycki claimed that the continued popularity of withdrawal in 
Turkey reflects widespread cultural and historical legitimacy of this method and 
there is little sign of withdrawal being replaced in Turkey anytime soon by 
modern methods [107]. 
Last, but not least, contraceptive choices themselves change, influenced by 
the multiple aspects of the context of women’s lives. Therefore, contraception is 
often a month-by-month rather than a concious strategy and the role of contra-
ceptive services is, thus, hard to overestimate [108]. 
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3.3.4. Contraception trends globally 
Analysis of contraceptive trends is challenging: the methodological differences 
between data sources complicate derivation of reliable estimates. United 
Nations Population Division provides systematic data about annual contra-
ceptive prevalence and unmet need for family planning among married women 
or women in union in age 15–49 of 194 countries or areas of the world from 
1970 [109]. 
According to the most recent data available, contraceptive prevalence varies 
between 4% in South Sudan and 88% in Norway. Worldwide, almost all regions 
had an increase in CPR from 54.8% (95% CI 52.3–57.1) in 1990, to 63.3% 
(60.4–66.0) in 2010 and a decrease in unmet need for family planning from 
15.4% (14.1–16.9) in 1990, to 12.3% (10.9–13.9) in 2010 [109,110]. The 
overall distribution of contraceptive methods has changed globally: the pro-
portion of sterilization has decreased, while that of long-acting reversible contra-
ception (LARC) has increased [111]. Nevertheless, for the world as a whole, 
female sterilization is still the most common method of contraception; more 
than half of contraceptive users worldwide relied on either female sterilization 
or the IUD. In developed regions as a whole, combined hormonal methods and 
condom accounted for more than half of all contraceptive use. Nine out of every 
10 contraceptive users in the world rely on modern methods of contraception. 
Traditional methods are the most commonly used in Middle Africa, Western 
Africa and Western Asia [109].  
To gain better insight into SH in EU, data about contraceptive prevalence 
were collected in the frame of the REPROSTAT project from 27 Member States 
in 2008 [112]. Data were obtained from a mixture of national surveys or other 
resources and are open to several limitations. However, despite these limi-
tations, CRP and a mix of contraceptive methods varied among Member States. 
Hormonal contraception was the most frequent contraceptive method used in 
most EU countries. Estonia was the country with the highest usage of with-
drawal, which tended to be, with rhythm method widely used in the eastern part 
of the EU. However, the overall use of modern methods increased in this region 
during the last two decades. 
 
3.3.5. Use of contraception in Estonia 
Estonia is a country with an early demographic transition like other “western” 
countries. In terms of fertility transition, Estonia had achieved below replace-
ment fertility already by the 1920s without the benefit of modern methods of 
contraception [113]. 
Since 1970, inert IUD and poor quality condoms with a high failure rate 
became erracticly available [64]. Hormonal contraceptive pills, available since 
1974, were almost banned for contraceptive purposes by the Soviet Union 
Ministry of Health. The warning label included a list of contraindications and 
side-effects not supported by evidence [64]. Textbook for medical students, 
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published in Estonia in 1981, suggested not to use hormonal contraception for 
more than one and half year and during this time monitor liver function and 
coagulation factors [114]. Because of lack of any evidence-based information, 
pills were distrusted by professionals. Usually women were advised against the 
pills and the public opinion was “physician-dictated” [64,65,115]. This created 
different cultural patterns, e. g., negative attitudes towards contraception com-
pared to the societies where contraception practice is widespread [64]. As a 
result, misinformation, misconceptions and rumours about modern contraceptive 
methods are still common. A further disincentive to the use of preventive 
methods was the fact that the state charged for contraceptives whilst abortion 
was free [115]. The lack of contraceptives of this time was very often 
mentioned in the Estonian sexual autobiographies reporting on sexual life after 
the first intercourse. Many women and men were constantly worried about 
unwanted pregnancy [116]. Since the early 1990s, all modern contraceptive 
methods have become available in Estonia. At the same time, abortion has been 
partly reimbursed. All students, women three months after abortion and one 
year after delivery got a 90% reimbursement for pills and IUDs. These benefits 
were replaced in 2000 by universal reimbursement of 50% for all contraceptive 
methods under prescription, copper IUDs are reimbursed to 100% during one 
year after delivery. In the middle of 1990s, emergency contraception was intro-
duced in Estonia and since 2000, it has had over-the-counter status. Male and 
female voluntary sterilization is legally regulated by the Termination of Preg-
nancy and Sterilisation Act adopted by the Riigikogu, the parliament of Estonia, 
at the end of 1998. 
 
There are no regular-based surveys or data collection regarding contraceptive 
usage in Estonia. A few population-based studies have included questions about 
contraception into their survey questionnaires. Most of them have several 
shortcomings, which did not make it possible to estimate CPR in country and 
making comparisons was also difficult. The first time, when survey data about 
contraception use in Estonia was presented, was during a survey carried out in 
Tartu in 1984 and it showed that 28% of women with one or more children 
attending outpatient clinics had used some modern contraceptive method, 3% 
had used hormonal pills, 13% IUD and 11% condoms [64]. The two rounds of 
Estonian Family and Fertility Survey (EFFS), a national part in the European 
Gender and Generation programme (in 1994 and 2004) had some questions 
about birth control [117,118]. In 1994, 3% of non-pregnant, sexually active 
women 20–49 years of age had used pills during the last month. The second 
round of EFFS ten years later calculated the cumulative use of contraceptive 
methods in birth cohorts from 1924 to 1983 and showed clearly that the use of 
pills and condoms increased among younger cohorts [118]. However, the pro-
portion of traditional methods was almost the same in all birth cohorts. In 2000, 
Elina Haavio-Mannila carried out ”Comparative Survey of Human and Intimate 
Relationships 2000” [119], the first SH survey in Estonia. The survey showed 
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that half of the respondents in need of contraception and having had intercourse 
in the past year had used modern contraceptive methods in his or her latest 
sexual intercourse. There was no gender difference in the likelihood of having 
used reliable contraceptive methods, but there was ethnic difference: Estonian-
speaking respondents had used reliable contraception more commonly than 
Russian-speaking respondents. 5% of Estonian-speaking and 14% of Russian-
speaking women had used no contraception even though they needed it. 
 
3.3.6. Contraceptive counselling in health care 
The primary purpose of contraceptive counselling is prevention of unintended 
pregnancies. Even though there is no standard definition, contraceptive coun-
selling is more than giving information – it is a form of interpersonal commu-
nication providing patients an opportunity to express their own values, wishes 
and concerns. Although the scope of this research is unintended pregnancy, 
access to and quality of contraceptive counselling is a part of overall family 
planning and preconception care.  
The most of effective contraceptive methods are available only by pre-
scription or must be inserted by a medical professional. Access, quality of care 
and medical barriers are the three main conceptual determinants relevant to the 
process from making contact with health care services to adopting contraceptive 
method [120]. Access to contraception has been defined by Bertrand: “Access is 
the degree to which services can be obtained at a level of effort and cost that is 
both acceptable to and within the means of a majority of the population” [120]. 
Access to SH care, including economic, geographic, phsycosocial and adminis-
trative access solely does not sufficiently address the problem of unintended 
pregnancy [75,120]. There is a general agreement that the quality of SH care 
influences individuals’ decisions to use contraception [121,122]. Promoting 
health care service quality was influenced by the establishment in 1990 of a 
framework that outlined the essential elements of the quality of care in family 
planning service delivery [123]. Bruce proposed a framework for assessing 
quality in family planning services from the patient’s perspective consisting of 
six parts – choice of contraceptive methods, information given to clients, tech-
nical competence, interpersonal relations, follow-up and continuity mecha-
nisms, and the appropriate constellation of services [123]. The framework also 
distinguishes information-giving from counselling with influencing clients’ 
confidence, satisfaction with services, and probability of continuity of care em-
powering individuals to make informed decisions. The patient’s rating of inter-
personal interactions is a process measure of satisfaction, addressing different 
qualities: responsiveness, friendliness, empathy, courtesy, confidenciality, com-
petence, and availability. However, there have also been critiques of the use of 
satisfaction as a measure of quality. In a review of the literature on patient satis-
faction Crow et al. argued [124] that satisfaction is a relative concept. There-
fore, what satisfies one person may dissatisfy another since their need or expec-
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tation of care may differ. Despite this, the studies capturing contraceptive coun-
selling have shown that patient’s satisfaction is related to return visits to the 
provider and with adherence to medical recommendations, readiness to con-
tinued care and adherence to therapy [125–127].  
The delivery and quality of general health services determine the provision 
and quality of SH services. The surveys on the use of health care services regu-
larly carried out in Estonia have shown high levels of satisfaction with both the 
primary care and specialized medical care. Since 2002, regular patient satis-
faction surveys have been carried out on behalf of the Ministry of Social 
Affairs. In 2008–2013, 86–92% of the respondents were very satisfied or gener-
ally satisfied with their visits to a family doctor and 87–90% with their visits to 
a medical specialist [128]. 
 
During the last two decades SH services have undergone profound changes in 
Estonia. Until beginning of the nineties, contraceptive counselling was provided 
exclusively by gynaecologists. Only recently, midwives and family nurses have 
become responsible for family planning issues. In addition to the women’s out-
patient clinics, new types of primary health care services offering contraceptive 
counselling were set up in the late 1990s: private gynaecological practices and, 
the YFC network. Although the SH services can be as stand-alone services, like 
YFC network in Estonia, it has been emphasized that contraceptive counselling 
should be integrated into primary care with referral if required [76,129]. 
Moreover, YFC are available only for young people under 25 years old. In 
countries where primary health care system is the main provider of contraceptive 
counselling, the prevalence of modern contraception is high and abortion rate is 
low. For example, in Finland health care services are offered equally to all 
residents – every municipality must have a health centre which provides, among 
other things, family planning services [44]. As for other Nordic countries, in 
1993, 99% of primary care doctors in Denmark, 94% in Iceland and 90% in 
Norway provided contraceptive counselling [130]. In Estonia, along with the 
reformation of the health care system in the nineties, family planning was 
included into primary care and became a part of family doctors professional 
standard. In a study conducted in 1993, only 2% of primary health care doctors 
reported that they had been ever prescribed hormonal contraception; in 2000, 
already 79% of family doctors agreed that family planning was their 
responsibility [131,132]. According to a study carried out in 1997, 59% of 
female respondents at the age of 18–50 considered it more convenient to visit a 
family doctor than a gynaecologist for family planning and 54% thought that a 
family doctor was able to take care of family planning [133]. 
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3.4. Intimate partner violence  
IPV is a behaviour within an intimate relationship that causes physical, sexual 
or psychological harm, including acts of physical aggression, all forms of sexual 
coercion, psychological abuse and controlling behaviours [14]. IPV between 
current or former spouses or partners together with intergenerational violence 
understood in criminal justice as “domestic violence” – that is, violence largely 
between family members, e.g., intimate partners, usually, though not exclu-
sively, taking place in the home [134]. Dating violence takes place within inti-
mate relationships, mostly among young people, has a varying duration and 
intensity and does not involve cohabiting. 
IPV and sexual violence are among the most pervasive forms of violence 
against women. Representing an assault on a person’s fundamental human 
rights, IPV may be both a sign and a consequence of gender discrimination – 
overwhelming majority of those experiencing IPV being women and the 
majority perpetrating it being men [134].  
Violence against intimate partner, is a major violation of human rights and 
public health concern. In addition to its human costs, IPV places an enormous 
economic burden on societies in terms of lost productivity and increased use of 
social and health services [14,134].  
 
3.4.1. Intimate partner violence determinants and prevalence 
IPV as a multifaceted problem has biological, psychological and social deter-
minants. Public health approach, the model firstly described by Heise, considers 
IPV the outcome of multiple risk factors and causes, interacting at four levels: 
individual, close relationship/family, community and wider society [14,134]. 
Over 50 risk factors of IPV have been identified and described in multiple 
studies [134]. Because of the complexity of the roots of IPV, this affects a large 
proportion of the population and occurs in all countries, irrespective of social, 
economic, religious or cultural group. In EU countries, women in various socio-
economic groups were equally exposed to victimisation [15]. Among all factors, 
two seem to be the most important for IPV: the unequal position of women in 
relationship and in society and the normative use of violence in conflict 
[14,15,134–136].  
Much of what is known about IPV prevalence comes from different surveys. 
The WHO Multi-Country Study on Women’s Health and Domestic Violence 
Against Women [137] involved more than 24,000 women between the ages of 
15 and 49 living in 10 low-and middle-income countries. The survey found that 
at some point in life, physical IPV was reported by 13–61% and sexual violence 
by 6–59% of the interviewees. In the US, a nationally representative survey 
among 16,507 women and men aged 18 and older showed that more than 1 in 3 
women (35.6%) had experienced IPV in their lifetime and 1 in 17 women had 
experienced IPV in the 12 months prior to the survey. Nearly 1 in 10 women 
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(9.4%) had been raped and 16.9% of women had experienced sexual violence 
other than rape by an intimate partner at some point in their lifetime [16]. For 
the first time, EU-wide data on 42,000 women at the age of 18–74 showed that 
22% of the women who were or had been involved in a relationship with a 
partner, had experienced physical and/or sexual IPV since the age of 15 and 8% 
of the women in the 12 months before the survey [15]. Considering the results 
at country level, the rates of life-time IPV range from 30–32% in Finland, 
Denmark and Latvia to 13% in Austria, Croatia, Poland, Slovenia and Spain. 
These and other studies indicate that psychological, physical and sexual IPV 
are closely intertwined – a majority of women who reported sexual IPV also 
reported physical IPV. For example, out of the women who had not experienced 
any form of psychological violence by their current partner, only 2% indicated 
that they had been physically or sexually abused by the same partner [15]. IPV 
rates vary greatly within and between countries and by data source. According 
to official police and other criminal justice statistics, IPV is largely under-
reported [134]. Not only differences resulting from the sources of data, various 
other factors affect the quality and comparability of data on IPV, including 
inconsistencies in the way violence is defined, variations in the selection criteria 
for study participants, the willingness of respondents to talk about violent expe-
riences. Violence is culturally determined – victimisation rates in surveys reflect 
the extent to which it is socially acceptable to talk about violence. Generally, 
higher rates of IPV tend to occur in lower-income countries, while increased 
gender equality leads to higher levels of disclosure about IPV. The EU Member 
States scoring higher on the Gender Equality Index also tend to have a higher 
prevalence of violence against women [15].  
 
3.4.2. Intimate partner violence and health  
IPV was ranked third among risks in terms of years of life lost owing to dis-
ability for women aged 15–49 years in the Global Burden of Disease Study 
2010 [138]. The influence of abuse can persist long after the abuse itself has 
stopped and the impact over time of different types of abuse, severity of abuse 
and of multiple episodes of abuse appears to be cumulative [17,18,139]. Serious 
adverse effects of IPV can last not only a lifetime, but span generations. 
Children who witness marital violence are at a higher risk for mental and 
physical health complaints [140]. The growing body of literature on the 
association of IPV and adverse health outcomes currently includes a range of 
methodological enquiries which allowed to show temporal pathways between 
IPV and many health consequences like somatic symptoms, poor sleep patterns, 
HIV, and aspects of mental health including depression, anxiety, and post-
traumatic stress disorder (PTSD) [18]. Numerous studies have documented 
increased risk for a number of adverse physical, mental, sexual, and other health 
outcomes among those who have experienced IPV [15–23]. Below conclusions 
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emerging from current research about the health consequences of IPV are 
described.  
IPV accounts for a significant number of deaths by homicide among women 
[141,142]. Fatal outcomes are also suicides [143], HIV-related deaths and 
maternal mortality. Women who have been abused experience reduced physical 
functioning, disabilities, activity limitations, more physical symptoms and lower 
self-rated health than non-abused women. More common physical outcomes of 
IPV are not physical injuries, but different physical symptoms which have no 
identifiable medical cause, such as gastrointestinal disorders and various 
chronic pain syndromes. Victims of IPV have an increased risk of chronic 
diseases like asthma, diabetes, joint disease. There are many theories as to why 
IPV victims have an increased risk of chronic diseases. Including a greater 
reporting of physical symptoms in general; or the adoption of health risk coping 
behaviours like smoking, binge drinking and other addictive disorders; or the 
increased prevalence of these conditions is attributable to the neurobiological 
response to chronic stress associated with violent experiences [144,145]. 
Well-known strong associations exist between IPV and mental health dis-
eases like PTSD [146–148], depression [149], generalized anxiety disorder, 
phobias, panic disorders, and substance abuse. Several studies of depression and 
IPV have suggested that IPV may be a stronger predictor of depression than 
cultural and sociodemographic factors or a prior mental illness [150,151].  
IPV is linked to sexual ill-health in many direct or indirect ways. Reduced 
autonomy is the result of an inequitable and coercive relationship and restricts 
ability to make sexual and reproductive choices [152–157]. Overt discussions 
and negotiations about contraception can be difficult in a violent relationship 
and result consistently in a higher level of contraception nonuse and incon-
sistent use of partner-dependent contraceptive methods [158]. Through coerced 
sex, IPV can lead directly to an unintended pregnancy and STI/HIV, or else 
indirectly by interfering with a woman’s ability to protect herself from an unin-
tended pregnancy and STI/HIV. IPV is associated with induced abortion [159]. 
Women who report having HIV or are unsure of their HIV status report more 
often IPV compared with women who are HIV-negative [160].  
There are also a variety of adverse gynaecological outcomes including an in-
creased risk of chronic pelvic pain, PID [161,162] and dysmenorrhea [163]. 
Sexual dysfunction has been associated with IPV, likewise has the risk of 
having cervical cancer [163]. Two studies found an association between IPV 
and hysterectomies [161,164].  
Violence and pregnancy is an extremely complex issue with consequences 
not only for the woman but also for the unborn child [165–168]. Prevalence 
rates of physical violence during pregnancy ranged between 3.0% and 10.9% and 
emotional abuse from 1.5% to 36% [168]. Pregnancy, often unwanted, can be the 
trigger for IPV with 14% of the respondents or escalate IPV with 64% [165]. 
Women who are pregnant and victims of IPV have high rates of stress, are more 
likely to smoke or use other drugs and are less likely to obtain prenatal care. 
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Experiencing assault during pregnancy is associated with a range of negative re-
productive outcomes, including infectious complications, spontaneous abortion, 
premature labour, antepartum haemorrhage and low-birth-weight babies  
[165–167]. 
 
The majority of victims of IPV and sexual violence do not seek immediate help. 
However, previous research suggests that IPVivictims make more visits to 
health providers over their lifetime, have a greater number of “bed days”, more 
and longer duration of hospital stays [145,169–171]. Therefore, health arena is 
an entry point for many victims of violence and a healthcare provider is likely 
to be the first professional contact for survivors of IPV – even if they do not 
disclose the associated violence [14,21,139]. This makes the health care insti-
tution an important place where women undergoing abuse can be identified, 
provided with support and referred to specialized services. Unfortunately, 
studies show that in most countries health care professionals rarely enquire of 
women whether they are being abused, or even check for obvious signs of vio-
lence [14,172]; and patients themselves seldom report their abusive experiences 
[173]. 
In recent years, attention has turned towards reforming the response of 
health care providers to victims of abuse. An overwhelming majority of women 
in the EU (87%) and in Estonia (90%) reported that it would be acceptable if 
doctors routinely asked women who have certain injuries whether those had 
been caused by violence [15]. Routine screening for the IPV by the health care 
providers is often recommended in literature [137,174,175]. American College 
of Obstetricians and Gynaecologists’ has seen screening of IPV as a core part of 
women’s preventive health visits [176]. A recent systematic review and meta-
analysis [177], guidance from the UK National Institute for Health and Care 
Excellence [178] and WHO [134] do not suggest routine screening in health 
care. However, health-care providers should ask about exposure to IPV when 
assessing conditions that may be caused or complicated by IPV and in antenatal 
care. Therefore, it is extremely important to know the health consequences 
associated with IPV to address violence in health care. 
 
 
3.4.3. Intimate partner violence in Estonia 
Studies about IPV in Estonia are relatively scarce. It was not until 2001 that the 
first IPV related survey was conducted in Estonia [24]. This showed that one 
fifth of women aged 15−74 were exposed to violence by someone during the 
previous year of which 63% took place at home. In 2002, a repetitive study 
including health issues yielded similar results: during the one-year study period, 
every fifth female was a victim of violence and two thirds were perpetated by 
an intimate partner [24]. The study revealed that almost every other case of 
violence ended with physical injuries for the woman, every sixth caused serious 
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injuries. Only one third asked for medical help, many victims have had long-
term consequences for mental health.  
In 2006, a survey “Behaviour of women in labour and home violence in 
Estonia” was carried out, results of which revealed that approximately one tenth 
of women who had recently given birth had been suffering from IPV during 
their last pregnancy by their present and one fifth by their prervious partner 
[180]. According to the results of the survey, IPV increased during pregnancy, 
physical violence in particular became more intensive [179]. 
In 2009, Statistics Estonia conducted a Safety Survey, one of the goals of 
which was to study occurrence of IPV [180,181]. The study considered that data 
on IPV are not reflected in the statistics about recorded offences compared with 
police statistics. According to the study, half of the 15–74-year-old women and 
men stated that they had at least once in their life been exposed to IPV, 39% had 
been exposed to psycological abuse, a third to physical abuse and 4% to sexual 
abuse since the age of 15. More than half had repeatedly been exposed to IPV, 
18% for more than five times. Female partners (32%) compared to males (6%), 
suffer more severe violence: beating, strangling, attack with a gun and sexual 
violence. 
A recent EU study found that 50% of Estonian respondents experienced 
psychological violence, 19% physical and 7% sexual IPV since the age of 15 
(the EU averages being 43%, 20% and 7%, respectively) [15]. Physical injuries 
sustained in the most serious incidents of physical and/or sexual violence by a 
partner since the age of 15 were experienced by 52% respondents in Estonia 
(the EU average being 42%). The most frequent long-term psychological con-
sequences of the most serious incidents of physical and/or sexual violence by a 
partner since the age of 15 were anxiety (32%) and depression (35%); 37% of 
the respondents reported loss of self-confidence, 30%, feeling vulnerable and 
28%, difficulties in sleeping [15].  
In 2014, a national population survey conducted among 1,111 Estonian 
inhabitants aged 15 and older mapped attitudes and awareness in the areas of 
domestic and gender-based violence. Slightly more than half of the people 
(54%) believe that the victim of domestic violence is to be blamed. Younger 
people, those with better education, higher income and living in the capital city 
and its surroundings as well as Estonians and women are significantly more 
sensitive to IPV [182].  
 
Studies indicate that IPV is a widespread and serious problem in Estonia. 
Despite that, in the EU survey, only 11% of women considered violence against 
women to be very common in Estonia compared to 27% in EU average [15]. 
Women’s overall low awareness of the specific legislation concerning pre-
vention of and protection from domestic violence in Estonia was two times 
lower than in EU average reflecting the country current situation about victims 
care [15]. 
 
9
34 
4. AIMS OF THE RESEARCH 
The overall aim of this research was to provide evidence on factors influencing 
women’s sexual health and reproductive choices in Estonia. 
 
In order to do that, the following specific aims were set:  
1. To describe induced abortion trends from 1996 to 2011 with an emphasis on 
sociodemographic characteristics and the use of contraceptive methods 
before abortion among women who underwent repeat abortions in Estonia 
(Paper I). 
2. To estimate prevalence rates of different contraceptive methods and to assess 
the impact of sociodemographic factors, reproductive history, sexual- and 
health-risk related factors on contraception use among different ethnic 
groups in Estonia and Russia, St. Petersburg (Paper II). 
3. To investigate use of, preferences for, and satisfaction with, contraceptive 
counselling by different contraceptive service providers among women over 
24 years old in Estonia (Paper III). 
4. To estimate the prevalence of intimate partner violence within the last 12 
months, and to explore the associations between intimate partner violence 
and reproductive choices and sexual health outcomes in Estonia (Paper IV). 
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5. MATERIALS AND METHODS 
This research is based on the data from the Estonian Abortion Registry (Paper I) 
and data of the cross sectional sexual health surveys (Paper II–IV).  
Surveys were conducted in Estonia (Paper II–IV) and St. Petersburg (Paper 
II) by REFER (Reproductive health, fertility patterns and family formation in 
Russia) – an international research consortium in the frame of the project 
“Reproductive Health and Fertility Patterns – A Comparative Approach” 
(http://www.valt.helsinki.fi/staff/rotkirch/RH_&_fertility_patterns.html). 
The questionnaire used in the surveys was compiled jointly by Estonian, St. 
Petersburg and Finnish researches from REFER. Panels of researchers 
negotiated a “best fit” for the translated questionnaires into target languages; 
each language version (English, Estonian, Russian) was compared with the 
others to ensure comparability [183]. The mastercopy of the questionnaire was 
in English; later translated into Estonian and Russian. The survey instrument 
used originated from the sexual health survey conducted in Finland in 1994 
[184] and later surveys [185–188]. The survey instrument used in Estonia and 
St Petersburg contained also site specific questions.  
The structured questionnaire used in Estonian Women’s Health Survey con-
sisted of 128 and that of St. Petersburg, of 109 questions covering the following 
domains:  
1. Sociodemographic characteristics  
2. Intimate relationships and sexuality 
3. Pregnancies and children 
4. Use of pregnancy and delivery related health care services 
5. Contraceptive methods 
6. Plans for having children 
7. Health and use of health care services 
The questionnaire was designed for self administration by the study parti-
cipants.  
 
 
5.1. Data sources and collection 
5.1.1. The Estonian Abortion Registry  
The EAR was established in 1994 [11]. Statistical data on abortions have rou-
tinely been collected since 1996. The instrument used for gathering data for the 
EAR about abortions is the Abortion Card, which includes data describing the 
abortion procedures, as well as each woman’s sociodemographic and re-
productive background. For every abortion, the Abortion Card is completed by 
a health care worker by interviewing the patient before the abortion procedure 
and using medical health records. All abortions, including spontaneous and 
induced abortions, e. g., induced abortions for medical reasons as well “other 
abortions” (coded by the International Classification of Diseases 10 as codes 
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O01, O02, O05, O06) are registered by health care institutions providing 
abortion care. Reporting is compulsory for all health care institutions, including 
all private health services. The coding, input, control, correction, saving and 
processing of data is carried out by the EAR registry on a regular basis. Since 
1999, by decree No43 of the Minister Social Affairs, the EAR has legally not 
been allowed to collect the patient’s personal identification number, which 
impairs and limits the linkage of abortion data.  
 
5.1.2. Estonian Women’s Health Survey 
In study size calculations it was taken into account that (a) in accordance with 
the Estonian Family and Fertility Survey [117] the percentage of sexually active 
women in the age groups 16–25, 26–35 and 36–44 years was 32.8, 66.5 and 
57.5 (a conservative estimate), respectively, and (b) the response rate was 
41.2% by the Human- and Intimate Relationship Survey 2000 [181]. If the res-
ponse rate in all age groups will be the same, then in order to reach statistically 
significant (significance level = 0,05; two-sided test; power 0,80; ratio of the 
group under consideration to an comparable group = 1:1) prevalence odds ratio 
of 2.5 in each age group when the variable (exposure) prevalence in comparable 
group is 0.10 (10%), the sample should be by age groups: 16–25 yrs – 2515, 
26–35 yrs – 1240 and 36–44 yrs – 1435 persons. The total sample size 5190 
guarantees that among responders there will be 340 sexually active women in 
each age group whose data will be further analyzed in the study. The program 
POWER, Epicenter Software, Pasadena, CA, USA was used for calculations. 
A random sample stratified by age of women aged 16 to 44 years was 
obtained from the Estonian Population Registry. A survey package containing 
an information letter, a self-administered questionnaire and a pre-stamped, pre-
addressed envelope was mailed to each participant. Survey participation was 
anonymous with a study code, being assigned to each study participant to pre-
vent personal identification. The respondent sent the study code back to the 
research team separately from the questionnaire in the other pre-paid and pre-
addressed envelope provided. Data were collected from May 2004 to February 
2005. A total of 5190 questionnaires (by age groups: 2515 questionnaires 
among 16−24-year-old, 1240 questionnaires among 26−34-year-old and 1435 
questionnaires among 35−49-year-old women, respectively), 3472 in the Esto-
nian and 1718 in the Russian language, were posted. Of the sample, 95 women 
did not live at the address recorded in the population registry, one was dead and 
seven did not respond for health related reasons. For non-responders of the first 
mailing (n=3113), the questionnaire was sent for the second time after 10−12 
weeks. Out of the 5087 potential respondents, 2335 did not return the ques-
tionnaire, 13 refused to answer, four questionnaires were completed unsatis-
factorily. Total response rate was 53.8% (n=2735). The data are presented in the 
respective survey report [189]. 
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 5.1.3. Reproductive Health and Fertility Survey in St. Petersburg  
In St. Petersburg, a different sampling and recruitment methodology was 
selected due to the absence of population registry, legal and other local circum-
stances. A random sample of study subjects was obtained from the database of 
the District Authority Police Department for the catchment areas of three 
outpatient clinics from two different districts (Krasnogvardeyskiy and Primorsky) 
out of 20, representative of St. Petersburg. The sample was stratified by age and 
by outpatient clinic. Total sample size was 2501 women (by age groups: 719 
questionnaires among 18−24-year-old, 858 questionnaires among 26−34-year-
old and 924 questionnaires among 35−49-year-old women, respectively). An 
initial invitation letter was mailed to women born between 1959−1985 (women 
aged 18−44). The letter contained information about the survey with an invita-
tion to attend to a specified women’s clinic to complete a self-administered 
questionnaire and have the opportunity to have an appointment with a 
gynecologist. A follow-up phone call was made to all potential respondents, 
during which, a second opportunity for a clinic or home visit was offered. For 
the 392 women who refused to visit the clinics, but indicated their interest to par-
ticipate in the survey or for those who did not have a phone number, ques-
tionnaires were taken into their home by study researchers. Data were collected 
from November 2003 to October 2004. Study participation was anonymous. Of 
the 1719 eligible respondents (782 women were not located or reached), 572 
refused to participate or contact was lost during the survey. Total response rate 
was 66.7%. The data are presented in the respective survey report [190].  
 
Table 1. Description of the survey designs in Estonia and St. Petersburg 
 Estonian Women’s Health 
Survey 
Reproductive Health and Fertility 
Survey in St. Petersburg 
Data source The Estonian Population 
Registry 
The database of the District 
Authority Police Department 
Sample frame The whole Estonian female 
population aged 16–44 (n=289 
830) 
Women aged 18–44 for the 
catchment areas of three outpatient 
clinics from two districts of St. 
Petersburg (n=90 532) 
Sample size 5190 – stratified by age (16−25, 
26−35 and 36−44 years)  
2501 – stratified by age (18−25, 
26−35 and 36−44 years) and by 
outpatient clinic 
Sampling Age stratified random sample 
(16−25, 26−35 and 36−44 
years) 
 
Two stage sampling: (1) selection of 
outpatient clinics; (2) followed by 
the age stratified random 
sampling(18−25, 26−35 and 36−44 
years) 
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 Estonian Women’s Health 
Survey 
Reproductive Health and Fertility 
Survey in St. Petersburg 
Study desing Cross-sectional postal survey 
Recruitment 
data 
collection 
A study package was sent by 
mail. For non-responders of the 
first mailing the questionnaire 
was sent for the second time 
after 10−12 weeks 
An invitation letter to attend to a 
specified women's clinic to 
complete a self-administered was 
mailed. A follow-up phone call was 
made to all potential respondents 
and questionnaires were taken to the 
homes of those who refused to visit 
the clinics, but indicated their 
interest to participate in the study, or 
for those who did not have a phone 
number 
Measurement A self-administered questionnaire 
Questionnaire  Adapted from Finnish studies (Raskaudenehkäisy1994; Health 2000; 
Finnriski 2002; National sex survey 1999). 
Data 
collection 
year 
2003–2004 2004–2005 
Response rate 53.8% 66.7% 
Incentives By lottery, three participants 
were awarded vouchers to get a 
3-day health package (with a 
value of EUR 60) 
A gift from a grocery store (with a 
value of EUR 5) 
 
Ethical  
Committee’s  
approval  
 
The Ethics Review 
Committee on Human Research 
of the University of 
Tartu, Estonia (107/65 
26.08.2002) 
The Ethical Committee 
of St. Petersburg Medical Academy 
of Postgraduate 
Studies (N6 24.09.2003) 
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5.2. Main outcome measures, study subjects and  
statistical analysis methods used in research 
5.2.1. The main outcome measures  
The main outcome measures of the research described here were:  
(1)  change in the proportion of repeated induced abortions over the two ob-
servation periods, 
(2)  self report on contraceptive behaviour (use at the most recent sexual inter-
course or prior to each abortion),  
(3)  contraceptive counselling (use of, preferred provider within the last 5 
years, and satisfaction with services for the last visit) and 
(4)  intimate partner violence (within the last 12 months).  
 
Induced abortion (paper I) 
The following data about induced abortions was obtained from EAR for the 
periods of 1996–2003 and 2004–2011: 
a)  annual numbers of the induced abortions (together with the aggregated data 
on indication for the abortion: medical or on request of the women);  
b)  annual numbers of the live births; and  
c)  aggregated data on selected sociodemographic characteristics (age, ethnicity, 
educational level, marital status, occupation) for the women undergoing 
abortions.  
In addition for the population based rates calculations population data on 
women aged 15–49 years for the periods of 1996–2003 and 2004–2011 was 
obtained from the Statistics Estonia.  
 
Contraceptive behaviour (papers I,II,IV) and contraceptive counselling (paper III) 
In paper I, contraception use prior to each abortion was assessed by asking: 
“What was the contraceptive method you used before becoming pregnant?” 
with the following response options on the Abortion Card: oral hormonal con-
traception, intrauterine contraception, condom, other, non-use, no data. Women 
could report several contraceptive methods, classification of method effec-
tiveness was based on the most reliable method reported. 
In paper II and IV contraceptive method during the most recent sexual inter-
course was elicited: respondents could choose a contraceptive method from a 
list of different methods (appendix Q 70). Based on available data about the 
effectiveness of contraceptive methods [44], all respondents who had used the 
rhythm method, withdrawal method, spermicides or vaginal douching were 
considered as having used an unreliable contraceptive method; those who had 
used hormonal contraceptive pills, patches, injectable hormonal contraceptive 
(Depo-Provera), emergency contraceptive pill, condom or IUD (questionnaire 
did not distinguish between hormone-releasing IUS and copper IUD) or under-
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gone sterilization were considered as having used a reliable contraceptive 
method. In the case of combined method use, the categorization of contra-
ceptive method was based on the most reliable method reported.  
In paper III, the use of, preferences for and satisfaction with friendliness, 
confidentiality, competence, and length of the visits for contraceptive coun-
selling at different health care service institutions – a women’s outpatient clinic, 
private gynaecological practices and general medical practices the last five 
years were measured based on participants self-reported assesments. Re-
spondents rated their satisfaction with the last visit in every aspect on a four 
step scale: very satified, rather satisfied, rather unsatisfied, very unsatisfied 
(appendix Q 79). For data analysis, the bineary variable was created (satified or 
unsatisfied). 
 
Intimate partner violence (paper IV)  
IPV was defined as physical or sexual violence by an intimate partner during 
the last 12 months prior to the survey. Intimate partner was defined as cur-
rent/former dating partner or husband (married or cohabiting). The violence 
module contained seven questions (appendix Q 107). An aggregate measure of 
violence was created, which was coded positive for respondents who reported 
either physical or sexual violence or both (IPV +) and negative (IPV –) if no 
exposure during the last year was reported. 
 
5.2.2. Study subjects  
Paper I 
According to the data from EAR the total number of the women who had 
undergone an induced abortion in the period of 1996–2011 was (144 070): 105 
938 abortions between 1996–2003 and 38 132 abortions between 2004–2011. 
Of those induced abortions 69% (105 758) were repeat abortions. According to 
the data from Statistics Estonia the total number of women aged 15–49 years in 
two time periods was 2 744 602 in 1996–2003 and 2 701 539 in 2004–2011. 
 
The data on study subjects (numbers, inclusion and exclusion criteria) and sub-
groups formed for the analysis for the research in Papers II−IV are presented on 
the Figures 2 to 4. 
 
Paper II  
Data on study participants is presented on Figure 2. Of 3208 screened for inclu-
sion to the analysis, data on 2478 were included. 
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Figure 2. Study subjects formed for the analysis in Paper II.  
 
Paper III 
Data on study participants is presented on Figure 3. Of 866 screened for inclu-
sion to the analysis, data on 835 were included. 
 
Figure 3. Study subjects formed for the analysis in Paper III.  
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Paper IV 
Data on study participants is presented on Figure 4. Of 2533 screened for inclu-
sion to the analysis, data on 1966 were included. 
 
Figure 4. Study subjects formed for the analysis in Paper IV.  
 
 
5.2.3. Statistical analysis 
Creating variables for the analysis 
The main independent variables in all papers used were self-reported socio-
demographic characteristics, reproductive history, sexual and health-related risk 
factors. 
Age was classified as follows: in paper I (≤19, 20–24, 25–29, 30–34, 35–39, 
40–44, ≥45 years), in paper II (20−24, 25−34, 35−44 years), in paper III: 
women at the age of 25−44, and in paper IV (16−24, 25−34, 35−44 years). In 
paper III, the respondent age was restricted to 25–44 years because of special 
interest for contraceptive services for women who did not have access to special 
youth clinics and 20−44 years in paper II because the St. Petersburg database 
included only five women under the age of 20.  
Nationality in paper I and native language in paper II–IV was used for 
categorization into different ethnic groups. In paper II only participants who 
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reported their native language either Estonian or Russian were included and 
defined as Estonians and Russians in Estonia. 
Educational level was divided into four (paper I), two (paper II,III) or three 
(paper IV) which engaged the answer options: basic/less, secondary, secondary 
special, university.  
Marital status was divided into four (paper I), two (paper II,III), three (paper 
IV) or based on answer options: married, cohabiting, divorced, separated, single. 
Economical subsistence, which was assessed with the question “Do you 
have difficulties with paying bills, for housing, electricity, heating, etc?” 
(appendix Q 16) and the responses were dichotomised as follows: never/ some-
times and often/ always, was used in papers II–IV. 
Occupation, divided as student, employed, unemployed and other, was used 
in I paper III. 
Residency, used in paper III, divides into five biggest cities in Estonia 
(namely: Tallinn, Tartu, Pärnu, Kohtla-Järve, Narva) and other. 
For reproductive history a combined variable was created to assess the 
interaction between history of births and abortions: no birth/no abortion, 
birth/no abortion, abortion/no birth, birth/abortion in paper II. In paper I and III 
number of lifetime births and abortions was used. 
To define sexual risk behaviour the following variables were used in paper 
II: >1 sexual partner during the last year; ≥5 sexual partners during lifetime; 
contraception nonuse or the use of unreliable contraceptive methods during the 
first act of sexual intercourse; parallel relationships during present marriage/ 
cohabitation. Respondents were categorized as having high-risk sexual behaviour 
if at least three of these four conditions were met. 
Smoking in paper II was divided into two categories: non-smoker and 
past/current smoker. 
Self-rated health in paper III was assesed by the question: “How do you 
rate your current level of health?” (appendix Q 94) and divided by two cate-
gories: very good/good/neither good nor bad and bad/very bad. 
Pregnancy intention in paper IV inquired about the most probable decision 
taken in case they got pregnant and the answer options were: would have a 
baby, would have an abortion, don’t know (including missing answers). 
 
Independent and dependent variables selected for the analysis 
Information on the main outcome measures (dependent variable in the analysis) 
for the research presented in papers II–IV is provided in the Sections 7.1.2. and 
7.1.3. 
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Table 2. Independent and dependent variables included in papers II–IV 
Paper Sociodemographic 
variables 
Other independent 
variables 
Dependent variables 
II Age, educational 
level, marital status, 
economical 
subsistence  
Reproductive history, 
sexual risk behavior, 
smoking 
Contraception non-use 
and the use of unreliable 
contraceptive methods 
during the most recent 
sexual intercourse among 
Estonians in Estonia, 
Russians in Estonia and 
Russians in St. Petersburg 
III Education, marital 
status, native 
language, economic 
subsistence, 
residency 
Self-rated health, use of 
different contraceptive 
counselling service 
providers  
Satisfaction with 
friendliness, 
confidentiality, 
competence, and length of 
the visit for contraceptive 
counselling  
IV Age, education, 
marital status, 
economical 
subsistence 
Contraceptive method 
used during the most 
recent sexual intercourse; 
condom use ever; repeat 
induced abortions; 
lifetime sexually 
transmitted infections 
(HIV/STIs), dyspareunia 
Experience of physical or 
sexual violence by an 
intimate partner during the 
last year 
 
Statistical analysis methods 
The data were analysed using the statistical package Stata 10. 
 
Paper I 
To characterise the trends in abortions and repeat abortions in Estonia in 
1996–2011, the following measures were calculated: 
1)  the abortion rate and fertility rate (i.e. the annual number of induced abor-
tions and live births, respectively, among women aged 15–49 years per 
1,000 women in that age group using the mid-year female population esti-
mates);  
2)  the abortion ratio (i.e. the annual number of induced abortions per 100 live 
births among women aged 15–49 years);  
3)  the age-specific abortion rates (i.e. the annual number of induced abortions 
among women in a specific age group per 1,000 women using the mid-year 
female population estimates in the same age group);  
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4)  the total abortion rate (i.e. the sum of 5-year age-specific abortion rates for 
women aged 15–49 years, multiplied by 5, calculated for a period, using the 
age-specific rates for that period). 
 
The period proportions (1996–2003 and 2004–2011) of women undergone 
repeat abortions by age groups were presented. The periods were choosen to 
better show the range and magnitude of changes in abortion statistics. 
To assess the association of the repeat abortions we used sociodemographic 
factors collected by EAR. The percentages of women undergone repeat abor-
tions were presented. For repeat abortion analysis all abortions for medical rea-
sons were excluded (3334 [3.0%] during 1996–2003 and 1927 [2.8%] during 
2004–2011).The percentage change (with 95% CIs) of repeat abortions within 
the selected sociodemographic subgroups has been calculated as a difference 
between respective observational periods (1996–2003 and 2004–2011) in the 
repeat abortions proportions divided by the proportion of specific subgroup in 
the first period.  
The formula that has been used is as follows:  
 
Percentage change = ି൫% ୧୬ ୤୧୰ୱ୲ ୮ୣ୰୧୭ୢ ଵଽଽ଺–ଶ଴଴ଷ൯ି (% ୧୬ ୱୣୡ୭୬ୢ ୮ୣ୰୧୭ୢ ଶ଴଴ସ–ଶ଴ଵଵ) % ୧୬ ୤୧୰ୱ୲ ୮ୣ୰୧୭ୢ  
 
The age distribution of 15–49 year olds women among women’s population in 
Estonia and the distribution of repeat abortions among the respective age groups 
were presented for 1996–2003 and 2004–2011. Distribution of the second, third, 
fourth and subsequent induced abortions among Estonians and non-Estonians 
and contraceptive method used prior to abortion were presented during the two 
time periods. 
 
Paper II  
Age-standardized prevalence rates and 95% CIs for selected contraceptive 
methods in study groups were calculated using the European standard popula-
tion. Exact binomial confidence intervals were calculated to compare the preva-
lence of different contraceptive methods in the age groups. Relative frequencies 
were used to describe sociodemographic, reproductive history and sexual and 
health-related characteristics of study respondents. AORs were calculated using 
age in model I and all variables (age, education, marital status, economic 
subsistance, reproductive history, high-risk sexual behaviour and smoking) in 
model II in a logistic regression model, made separately for each study group 
(Estonians, Russians in Estonia and Russians in St. Peterburg). 
 
Paper III 
Relative frequencies were used to describe sociodemographic, reproductive 
history and self reported health of study respondents by health care institution. 
The odds of satisfaction with friendliness, confidentiality, competence, and 
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length of the visit was assessed and expressed as an adjusted odds ratio (AOR) 
and its 95% confidence interval (95% CI) adjusted for all independent variables 
an calculated using the method of logistic regression.  
 
Paper IV  
Prevalence of physical and sexual IPV and both during the last 12 months was 
presented. Relative frequencies were used to describe sociodemographic and 
reproductive history characteristics of study respondents. Differences between 
respondents having and having not been exposed to IPV were tested by chi-
square test. Sociodemographic factors that were statistically significantly related 
to IPV exposure (age, education, economic subsistence and language) were 
entered into five multivariate logistic regression models exploring associations 
between IPV exposure and selected sexual health outcomes (contraception 
nonuse; use of unreliable contraceptive method; having never used a condom; 
having a repeat induced abortion; lifetime STI/HIV; and dyspareunia). Asso-
ciations are presented as crude odds ratios and AORs 95% CIs. Contraceptive 
method during the most recent sexual intercourse was presented by IPV exposure. 
 
In papers II–IV, for categorical variables, descriptive statistics (absolute and 
relative frequencies) are presented. Descriptive statistics for sub-samples of 
interest, such as ethnic groups are also presented in paper II. Correlates for 
selected outcomes (dependent variables) were explored using the chi-square test 
for proportions, Fisher’s exact test for small cell expected values (<5) and uni-
variate logistic regression analysis. Multivariate logistic regression analysis to 
assess confounding and interaction between variables. All factors (Paper II, III) 
or factors with p < 0.05 (Paper IV) in univariable analysis were entered in a 
multivariable comparison. Crude odds ratios (OR) from univariable and 
adjusted odds ratios (AOR) from multivariable analysis together with 95% con-
fidence intervals (CI) are presented.  
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6. RESULTS 
6.1. Induced abortion in Estonia (paper I) 
6.1.1. Trends on induced abortion  
Figure 5 presents the trends relating to induced abortion rate, fertility rate and 
abortion ratio during 1996–2011. In 1996, the annual number of induced abor-
tions was 16,887 equating to an abortion rate of 48.3 and abortion ratio of 
128.7. In 2011, the respective figures were 6,689, 20.7 and 45.0, which repre-
sents a reduction in abortion rate of 57.1% and an abortion ratio of 65.0%. 
During the same time period, the total abortion rate dropped from 1.72 to 0.71. 
Alongside this consistent decline in the number of induced abortion, there was a 
22.9% increase in fertility rate. The maximum number of abortions that any 
woman admitted to requesting was 30 in 1996 and 17 in 2011.  
 
Figure 5. Fertility rate, induced abortion rate and ratio, Estonia, 1996–2011. 
 
The distribution of age-specific induced abortion rates was similar in 1996 and 
2011, whereas the abortion rates across all age groups markedly declined over 
the same period. Women aged 20–29 years accounted for approximately half of 
all induced abortion patients (49.4% in 1996 and 47.1% in 2011) showing the 
highest and steepest decline in abortion rates (65.3% among 20–24 year olds 
and 64.4% among 25–29 year olds) throughout the observed period. Teenagers’ 
(≤ 19 years) induced abortions accounted for 12.3% of all induced abortions in 
1996 and 9.7% in 2011 showing a decrease in abortion rate of 56.7%. A smaller 
decline in abortion rates was observed among older women (55.4% among 30–
34 year olds; 47.3% among 35–39 year olds; 41.2% among 40–44 year olds). 
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6.1.2. Repeat abortion 
For induced abortions on request, repeat abortions were obtained by 63.8% 
(n=67,626) of the women during 1996–2003 and 58% (n=38,132) during 2004–
2011. In 1996–2003 and 2004–2011, 26% of the women were seeking their 
second abortion; 17.2% and 15.9% their third; 20.6% and 16.1% their fourth or 
higher-order abortion. Among the target population the proportion of 20–24 and 
25–29 year olds women was higher in the second observational period, but the 
proportion of repeat abortion in these age groups was lower compared to 1996–
2003 (Figure 6).  
 
 
Figure 6. Age distribution of women aged 15–49 years among mid-year female popu-
lation estimates in 1996–2003 and in 2004–2011, and proportions of repeat abortion 
among the respective age group in Estonia.  
 
The proportion of women who underwent repeat abortions decreased across all 
the sociodemographic subgroups during the study period, but most significantly 
among women under 30 years of age, women with a university degree and 
nulliparous (Table 3). For women with a basic or less education and students 
the change was not statistically significant. The proportion of women with a 
basic or less education undergone repeat abortion increased from 7.7% in 1996 
to 19.2% in 2011. Although the proportion of women undergone repeat abortion 
decreased within both ethnic groups during the study period, the proportion of 
women seeking fourth or subsequent abortion was two times higher among non-
Estonians compared to Estonians (Figure 7). 
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Table 3. Percentage change and 95% confidence intervals (95% CI) of repeat abortions 
between two periods (1996–2003 and 2004–2011) within selected socio-demographic 
and parity subgroups in Estonia 
 
Characteristic Percentage change (95% CI) 
Age (years) 
≤19 –14.6 (–19.4; –9.4)
20–24 –15.0 (–16.8; –13.1)
25–29 –10.4 (–11.8; –9.1)
30–34 –7.2 (–8.3; –6.0)
35–39 –6.3 (–7.4; –5.2)
40–44 –5.2 (–6.7; –3.7)
≥45  –6.1 (–11.1; –0.8)
Education 
University –17.3 (–19.1; –15.5)
Secondary –4.5 (–5.6; –3.3)
Secondary special –6.1 (–7.3; –4.9)
Basic/less   –1.4 (–1.2; 4.1)
Ethinicity 
Estonian –8.9 (–9.9; –7.9)
Non-Estonians –7.7 (–8.7; –6.7)
Marital status 
Single –2.4 (–4.3; –0.4)
Married –6.8 (–7.8; –5.8)
Cohabiting   –3.7 (–5.0; –2.3)
Divorced/widow   –7.7 (–9.6; –5.7)
Occupation 
Student   –3.1 (–8.0; 2.0) 
Employed   –7.7 (–8.5; –6.9) 
Unemployed   –8.9 (–11.3; –6.5)
Other   –3.4 (–4.9; –1.8)
Parity 
0 –15.7 (–18.3; –13.0)
1   –8.1 (–9.2; –7.0)
2+   –4.5 (–5.3; –3.7)
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Figure 7. Distribution of the second, third, fourth and subsequent among all induced 
abortions on request among Estonians and non-Estonians in 1996–2003 and 2004–2011. 
 
 
6.2. Contraception (papers I–III) 
6.2.1. Contraception prior to abortion (paper I) 
Contraceptive nonuse prior to abortion was reported by more than half of 
women having an abortion; while the failed use of contraceptive pills and 
intrauterine contraception was low at the time of first, second, third or fourth or 
subsequent abortions (Table 4). Condom was the most frequently reported 
failed contraceptive method prior to all abortions during 2004–2011, and prior 
to a first or second abortion in 1996–2003. For women undergone their third, 
fourth or subsequent abortion during 1996–2003, the most frequently reported 
contraceptive methods were classified as “other” (rhythm method, withdrawal, 
spermicides). Within each time period, the proportion of women using “other” 
contraceptive methods increased as the number of abortions obtained increased, 
but overall, there was a decrease in the use of these methods over the 16-year 
period. 
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Table 4. Contraceptive use (%) prior to abortion among women obtaining the first, 
second, third and fourth or higher-order abortion in Estonia in 1996–2003 and 2004–
2011 
Contraceptive 
method 
1996–2003  2004–2011 
N=105 938 N=65 735 
1st 2nd 3rd 4th+ 1st 2nd 3rd 4th + 
Non-use 58.5  55.5 54.5 54.7  65.5 63.8 65.0 65.3 
Pill 4.1 5.6 5.1 4.6 5.1 6.1 6.0 5.2 
IUD 2.4 2.7 2.9 2.2 1.5 1.6 1.6 0.9 
Condom 18.4 16.3 15.7 14.3 18.1  15.6 14.1 13.4 
Other 12.0  15.8 17.4 20.3 7.3 10.2 11.0 13.1 
Missing 5.4 5.2 5.5 5.2 3.0 3.2 2.8 2.8 
 
 6.2.2. Contraceptive behaviour in Estonia and  
St. Petersburg (paper II) 
Table 5. Distribution of selected characteristics of 20–44-year-old women in Estonia 
and in St. Petersburg (Russia), n (%) 
Characteristic Estonians in 
Estonia 
Russians in 
Estonia 
Russians in  
St. Petersburg 
Total 1189 (100) 491 (100) 798 (100) 
Sociodemographic    
Age     
20–24 411 (34.6) 172 (35.0) 177 (22.2) 
25–34 396 (33.3) 159 (32.4) 268 (33.6) 
35–44 382 (32.1) 160 (32.6) 353 (44.2) 
Marital status    
Married 372 (31.3) 212 (43.2) 402 (50.4) 
Cohabiting 464 (39.0) 126 (25.7) 117 (14.7) 
Single 205 (17.2) 106 (21.6) 175 (21.9) 
Other 143 (12.0) 45 (  9.2) 98 (12.3) 
Missing  5 (  0.4) 2 (  0.4) 6 (  0.8) 
Education    
University 299 (25.1) 126 (25.7) 274 (34.3) 
Secondary special 438 (36.8) 212 (43.2) 313 (39.2) 
Secondary 386 (32.5) 126 (25.7) 190 (23.8) 
Basic/less 62 (5.2) 24 (  4.9) 17 (  2.1) 
Missing  4 (0.3) 3 (  0.6) 4 (  0.5) 
Description of study subjects 
Respondents’ background characteristics are presented in Table 5. 
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Characteristic Estonians in 
Estonia 
Russians in 
Estonia 
Russians in  
St. Petersburg 
Difficulties with paying bills    
Never 284 (23.9) 112 (22.8) 184 (23.1) 
Sometimes 717 (60.3) 243 (49.5) 432 (54.1) 
Often/always 172 (14.5) 133 (27.1) 169 (21.2) 
Missing  16 (  1.3) 3 (  0.6) 13 (  1.6) 
Reproductive history    
Birth    
No 435 (36.6) 156 (31.8) 234 (29.3) 
Yes 754 (63.4) 334 (68.0) 564 (70.7) 
Missing  − 1 (  0.2) − 
Abortion    
No 684 (57.5) 226 (46.0) 331 (41.5) 
Yes 505 (42.5) 264 (53.8) 467 (58.5) 
Missing  − 1 (  0.2) − 
Sexual and health risk factors    
Number of sexual partners 
during last year 
   
1 911 (76.6) 344 (70.1) 610 (76.4) 
>1 247 (20.8) 123 (25.1) 152 (19.0) 
Missing  31 (  2.6) 24 (  4.9) 36 (  4.5) 
Number of sexual partners 
during lifetime 
   
<5 652 (54.8) 243 (49.5) 426 (53.4) 
≥5 483 (40.6) 206 (42.0) 283 (35.5) 
Missing  54 (  4.5) 42 (  8.6) 89 (11.2) 
Parallel relationship during  
present marriage/cohabitation 
   
No 713 (60.0) 259 (52.7) 503 (63.0) 
Yes 173 (14.6) 98 (20.0) 157 (19.7) 
No present 
marriage/cohabitation  
288 (24.2) 119 (24.2) 127 (15.9) 
Missing  15 (  1.3) 15 (  3.1) 11 (  1.4) 
Contraceptive method during 
the first intercourse 
   
Reliable  386 (32.5) 149 (30.3) 230 (28.8) 
Unreliable  410 (34.5) 152 (31.0) 230 (28.8) 
Contraception nonuse 365 (30.7) 175 (35.6) 317 (39.7) 
Missing  28 (  2.4) 15 (  3.1) 21 (  2.6) 
Smoking    
Never  643 (54.1) 189 (38.5) 322 (40.4) 
Past smoker 192 (16.1) 88 (17.9) 117 (14.7) 
Current smoker 348 (29.3) 212 (43.2) 351 (44.0) 
Missing  6 (0.5) 2 (  0.4) 8 (  1.0) 
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Prevalence of contraceptive methods in Estonia and St. Petersburg  
The use of unreliable contraceptive methods were widespread in all study 
groups, but significantly lower among Estonians (20.4%; 95% CI 18.0–22.8) 
compared to Russians in Estonia (33.8%; 95% CI 29.4–38.2) and in St. Peters-
burg (31.4; 95% 28.1–34.7) (Figure 8). A remarkable proportion of respondents 
in St. Petersburg (7.7%) and Russians in Estonia (3.4%) considered vaginal 
douching to be a contraceptive method. Among Russians in Estonia and in St. 
Petersburg, the most prevalent method used at the most recent sexual inter-
course was using condom (respectively 30.3% and 41.3%), followed by the 
withdrawal method (21.8% and 18.2%) (Figure 9). The use of withdrawal and 
rhythm methods showed contrasting trends with respect to age in all study 
groups (Table 6). Hormonal contraceptive methods, of which more than 98% 
were contraceptive pills, had been used significantly more frequently by Esto-
nians (29.1%), while condoms were used more frequently by respondents in St. 
Petersburg and Russians in Estonia. Use of contraceptive pills and condom 
decreased with age in all study groups, but among Russians in St. Petersburg 
condom use was still relatively high in older age groups. IUD use showed an 
increasing trend with age in all countries, but was used almost three times more 
frequently in Estonia compared to respondents in St. Petersburg. Use of a com-
bination of different contraceptive methods was reported by 14.1% of Esto-
nians, 27.1% of Russians in Estonia and 22.4% of women in St. Petersburg. The 
most common combinations were the pill plus condom among Estonians, with-
drawal plus rhythm methods among Russians in Estonia and withdrawal method 
plus condom in St. Petersburg.  
Figure 8. The prevalence of contraceptive nonuse, use of unreliable and reliable contra-
ceptive methods among Estonians in Estonia, Russians in Estonia and Russians in St. 
Petersburg, 2004. 
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Figure 9. The prevalence of different contraceptive methods among Estonians in 
Estonia, Russians in Estonia and Russians in St. Petersburg, 2004. 
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Table 6. Contraceptive prevalence rates (%) and 95% confidence interval (CI) among 20–44-year-old 
women by age group in Estonia and in St. Petersburg (Russia), 2004 
Study group/ 
Contraceptive method 
Prevalence proportion (95% CI) 
20–24 25–34 35–44 Totala 
Estonians in Estonia      
Reliable methods 77.6 (73.2–81.6) 73.5 (68.8–77.8) 69.6 (64.8–74.2) 73.7 (70.1–75.4)
Pills 46.0 (41.1–50.9) 27.8 (23.4–32.5) 22.0 (17.9–26.5) 29.1 (26.5–31.7)
Condom 33.1 (28.6–37.9) 27.8 (23.4–32.5) 16.5 (12.9–20.6) 24.4 (21.9–26.9)
IUD   2.4 (1.2–  4.4) 21.5 (17.5–25.8) 30.4 (25.8–35.2) 21.1 (18.6–23.6)
Emergency contraception   0.2 (0.0–  1.3)   1.3 (0.4–  2.9)   2.4 (1.1–  4.4)   1.5 (0.8–  2.3)
Unreliable methods 18.2 (14.6–22.3) 21.7 (17.8–26.1) 20.2 (16.2–24.5) 20.4 (18.0–22.8)
Withdrawal 15.6 (12.2–19.4) 14.9 (11.5–18.8) 10.5 (7.6–14.0) 13.2 (11.3–15.2)
Rhythm   4.1 (2.4–6.5)   7.6 (5.2–10.6)  9.9 (7.1–13.4)   7.8 (6.2–9.4)
Vaginal douching   1.0 (0.3–2.5)   1.0 (0.3–2.6)  1.6 (0.6–3.4)   1.2 (0.6–1.9)
Spermicides   0.2 (0.0–1.3)   1.3 (0.4–2.9)   2.6 (1.3–4.8)   1.6 (0.8–2.4)
Non-use   4.1 (2.4–6.5)   4.8 (2.9–7.4) 10.2 (7.4–13.7)   6.9 (5.4–8.4)
Russians in Estonia  
Reliable methods 62.2 (54.5–69.4) 60.4 (52.3–68.0) 59.4 (51.3–67.1) 60.1 (55.6–64.7)
Pills 19.8 (14.1–26.5) 18.2 (12.6–25.1)   8.1 (4.4–13.5) 14.4 (11.3–17.6)
Condom 40.7 (33.3–48.4) 27.7 (20.9–35.3) 27.5 (20.7–35.1) 30.3 (26.1–34.5)
IUD   6.4 (3.2–11.2) 22.6 (16.4–29.9) 28.8 (21.9–36.4) 21.7 (17.8–25.6)
Emergency contraception            –   0.6 (0.0–3.5)   0.6 (0.0–3.4)   0.5 (0.0–1.1)
Unreliable methods 34.3 (27.2–41.9) 36.5 (29.0–44.4) 30.6 (23.6–38.4) 33.8 (29.4–38.2)
Withdrawal 29.1 (22.4–36.5) 25.2 (18.6–32.6) 15.0 (  9.9–21.5) 21.8 (18.0–25.5)
Rhythm   8.1 (4.5–13.3) 12.6 (7.9–18.8) 18.8 (13.0–25.7) 14.3 (11.0–17.6)
Vaginal douching   7.0 (3.7–11.9)   2.5 (0.7–6.3)   2.5 (0.7–6.3)   3.4 (1.8–4.9)
Spermicides   1.2 (0.1–4.1)   5.7 (2.6–10.5)   4.4 (1.8–8.8)   4.4 (2.4–6.4)
Non-use   3.5 (1.3–7.4)   3.1 (1.0–7.2) 10.0 (5.8–15.7)   6.0 (3.8–8.3)
Russians in St. Petersburg  
Reliable methods 66.1 (58.6–73.0) 62.3 (56.2–68.1) 47.9 (42.6–53.2) 57.5 (54.1–61.0)
Pills 19.8 (14.2–26.4) 13.1 (9.3–17.7)   7.1 (.6–10.3) 11.8 (9.6–14.1)
Condom 46.9 (39.4–54.5) 48.1 (42.0–54.3) 30.6 (25.8–35.7) 41.3 (37.9–44.8)
IUD   1.7 (0.4–4.9)   5.2 (2.9–8.6) 14.2 (10.7–18.2)   8.1 (6.2–9.9)
Emergency contraception   0.6 (0.0–3.1)   0.4 (0.0–2.1)   1.1 (0.3–2.9)   0.7 (0.1–1.2)
Unreliable methods 24.3 (18.2–31.3) 31.7 (26.2–37.7) 33.7 (28.8–38.9) 31.4 (28.1–34.7)
Withdrawal 20.9 (15.2–27.6) 20.5 (15.6–25.9) 13.9 (10.4–17.9) 18.2 (15.4–20.9)
Rhythm   2.3 (0.6–5.7)   8.2 (5.2–12.2) 14.4 (11.0–18.6)   9.8 (7.7–11.9)
Vaginal douching   5.1 (2.4–9.4)   6.7 (4.0–10.4) 10.5 (7.5–14.2)   7.7 (5.9–9.6)
Spermicides   2.8 (0.9–6.5)   6.0 (3.5–9.5)   3.1 (1.6–5.5)   4.4 (2.9–5.9)
Non-use   9.6 (5.7–14.9)   6.0 (3.5–9.5) 18.4 (14.5–22.9) 11.1 (9.0–13.2)
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Multivariate logistic regression analysis adjusted for age, marital status, edu-
cation, economic subsistence, reproductive history, high-risk sexual behavior 
and smoking showed that Estonians in older age groups (AOR 2.20; 95% CI 
1.41−3.41), those who had difficulties with paying bills (AOR1.64; 95% CI 
1.14−2.37), had high-risk sexual behavior (AOR 1.44; 95% CI 1.00−2.08) and 
past or current smokers (AOR 1.42; 95% CI 1.07−1.89) were at a higher risk of 
an unmet need for contraception. The same pattern was not observed among 
Russians in Estonia and respondents in St. Petersburg. Previous childbirth and 
abortion were associated with decreased odds of unmet need for contraception 
among Estonians (AOR 0.50; 95% CI0.31−0.81) and elevated odds (AOR1.99; 
95% CI 1.17−3.40) among respondents in St. Petersburg. Abortion experience 
alone was positively correlated with unmet need for contraception among 
Russians in Estonia (AOR 2.94; 95% CI 1.25−6.95).  
 
6.2.3. Contraceptive counselling in Estonia (paper III) 
61% of women aged 25–44 years had visited some health care institution for 
contraceptive counselling during the five years prior the survey. The majority of 
respondents visited (74%) and preferred (67%) the contraceptive counselling 
provided by a gynaecologist in a women’s out-patient clinic; the remainder had 
made use of and preferred private gynaecological practices (17% and 17%, 
respectively) and general medical practices (9% and 7%). At least 81% of the 
respondents were satisfied with all studied aspects of care in the different types 
of service providers (Figure 10). The women who visited health care institution 
preferred by them and who had higher self-rated health were significantly more 
satisfied with contraceptive care. The respondents who reported their native 
language other than Estonian were less satisfied with friendliness and com-
petency. Living outside five big cities in Estonia was positively correlated with 
the satisfaction with the length of visit. Women were more likely to be satisfied 
with friendliness, confidentiality, competence and the length of the visit in other 
types of service providers compared with women’s out-patient clinics; the rela-
tion was statistically significant for the length of visit (AOR 2.84 95% CI 1.31–
6.18) and confidentiality (AOR 2.44 95%CI 1.05–5.67) in private gynae-
cological practices, and for the length of visit in general medical practices 
(AOR 5.97 95% CI 1.38–25.82). 
 
Factors associated with contraception nonuse or the use of unreliable contraceptive 
methods among different ethnic groups  
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Figure 10. Satisfaction with competency, confidenciality, friendliness and lenght of the 
visit in different health care services providing contraceptive counselling in Estonia, 
2004 (%). 
 
 
6.3. Intimate partner violence in Estonia (paper IV) 
6.3.1. Prevalence of intimate partner violence  
Out of 1,966 respondents, 362 (18.4%; 95% CI 16.7–20.2) women reported 
physical or sexual IPV or both during the last 12 months. The most common 
type of IPV was physical violence 17.2% (95% CI 15.6–19.0) of all respondents 
and 93.6% (95% CI 90.6–95.9) of IPV survivors), followed by sexual violence 
4.1% (95% CI 3.2–5.0) and 22.1% (95% CI 17.9–26.7), respectively), 1.8% 
(95% CI 1.2–2.5) of all respondents and 9.7% (95% CI 6.8–13.2) of IPV survi-
vors had been exposed to both types of violence.  
Out of 1,966 respondents, 362 (18.4%) women reported physical or sexual 
IPV or both during the last 12 months. The most common type of IPV was 
physical violence (17.2% of all respondents and 93.6% of IPV survivors), fol-
lowed by sexual violence (4.1% and 22.1%, respectively), 1.8% of all respond-
ents and 9.7% of IPV survivors had been exposed to both types of violence 
(n=35). In table 7, prevalence estimates of different types of IPV are presented. 
Factors associated with IPV exposure were younger age (p≤ 0.05), lower edu-
cational level (p≤ 0.01), non-Estonian ethnicity (p≤ 0.01) and lower economical 
subsistence (p≤ 0.01). In the IPV exposure group more women had had induced 
abortions, but the number of births was similar in the two study groups.  
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Table 7. Intimate partner violence (IPV) during the last 12 months grouped according 
to type of violence in Estonia, 2004 
Type of IPV violence  Percentage of all 
respondents  
(95% CI) 
Percentage of IPV 
survivors  
(95% CI) 
Threatened with physical violence     8.1 (6.9–9.4) 43.9 (38.7–49.2) 
Pushed, shaken, had something thrown  14.2 (12.7–15.9) 77.3 (72.7–81.6) 
Hit with something that caused/could have 
caused physical injury 
5.2 (4.3–6.3) 28.5 (23.9–33.4) 
Threatened with a knife/gun/other object     1.0 (0.6–1.6)    5.5 (3.4–8.4) 
Physically forced to have sexual intercourse 1.7 (1.2–2.4) 9.4 (6.6–12.9) 
Threatened/frightened into having sexual 
intercourse 
1.1 (0.7–1.6)    5.8 (3.6–8.7) 
Forced to participate in other sexual acts 2.1 (1.5–2.9) 11.6 (8.5–15.4) 
 
6.3.2. Intimate partner violence and  
selected sexual health outcomes 
A vast majority of the respondents reported using some contraceptive method 
during their most recent sexual intercourse. The pattern of contraceptive use 
differed by IPV exposure – reported use of hormonal contraceptive methods and 
condom was lower and contraceptive nonuse and the use of unreliable con-
traceptive methods was higher among the respondents exposed to IPV com-
pared to those who had not been exposed to IPV (Table 8).  
 
Table 8. Use of contraceptive method (%) at the most recent intercourse by a  
respondent exposed to intimate partner violence during the last 12 months in Estonia, 
2004* 
Contraceptive method IPV+ 
n=362 
IPV− 
n=1604 
Hormonal methods 19.6 25.9 
IUD 16.0 15.1 
Condom 17.7 24.9 
Sterilisation 0.3 0.9 
Emergency contraception 0.6 1.2 
Unreliable methods 27.9 20.3 
None 8.6 5.1 
Missing 0.0 0.5 
*Respondents could report several contraceptive methods; classification of method effectiveness 
was based on the most reliable method reported. 
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Multivariate logistic analysis showed that IPV during the last 12 months, before 
and after adjustment for potential confounders (age, education, economic sub-
sistence, ethnicity), was significantly associated with adverse sexual health out-
comes. The risk for contraception nonuse (AOR 2.02; 95% CI 1.44−2.82); use 
of unreliable contraceptive method (AOR 1.54; 95% CI 1.16−2.04); having 
never used a condom (AOR 1.53; 95% CI 1.12−2.10); having a repeat induced 
abortion (AOR 1.72; 95% CI 1.24−2.37); STI/HIV (AOR 2.05; 95% CI 
1.56−2.68); and dyspareunia (AOR 2.14; 95% CI 1.65−2.77) was significantly 
higher among IPV survivors. 
A significant difference was found between the two study groups regarding 
intentions in the hypothetical case of pregnancy. More IPV exposed women, 
compared to the non-exposed ones, reported that they would opt for an abortion 
(26.2% vs. 22.1%, p<0.001) or expressed ambivalence about the decision 
(34.8% vs. 26.3%, p<0.001). The proportion of respondents who did not use 
contraception because they were planning pregnancy was higher among IPV 
exposed group compared to the respondents with no IPV exposure (27.9% vs. 
20.3%, p<0.001). 
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7. DISCUSSION 
To the author’s knowledge this series of studies is the first in Estonia to docu-
ment data on significant health indicators for the SH domains of respect of 
sexual rights to have a safe, pleasurable sexual life and fertility regulation.  
The results show a considerable decline in the number of induced abortions and 
a slow decline in the number of repeat abortions performed in Estonia over the 
period of 1996–2011. Although satisfaction with contraceptive counselling in 
health care was high, results suggest a high unmet need for contraception 
among many women, especially those of an ethnic minority group. The high 
prevalence of IPV violence was an important contributor to sexual risk 
behaviour and adverse sexual health outcomes among women of childbearing 
age. 
 
7.1. Trends of induced abortion and repeat abortion 
Over the 16-year study period of 1996–2011 there was a reduction in the overall 
abortion rate and a consistent decline in repeat abortions in Estonia. Today, 
every third pregnancy in Estonia ends with induced abortion. The abortion rate 
and the number of repeat abortions, and especially the number of third and 
higher-order abortions, is high compared with many other developed countries. 
For instance, in 2011, among all induced abortions, the proportion of women 
undergoing fourth and subsequent abortions was 17.9% in Estonia, compared to 
5.6% in Sweden and <1% in England and Wales [70,72]. A high percentage of 
women who have undergone repeat abortions reflect a high historical abortion 
rate. Currently, the highest percentage of women undergoing repeat abortions 
are those in their 30s and 40s who have either had several abortions in their 
lifetime, or had a greater number of repeat abortions when younger. Thus, it can 
be assumed that when older cohorts of women “age out” of their reproductive 
years, a more rapid decline in the number of repeat abortions is likely to happen 
in future years. This hypothesis is also supported by evidence that the overall 
decline in abortion rate observed during the study period was mainly attributed 
to younger cohorts who have shown a higher acceptance of effective contra-
ceptive methods than older women. Moreover, despite the increased proportion 
of women aged 20–29 in the population during the study periods, the proportion 
of repeat abortions among this age group decreased. The peak abortion rate was 
consistently observed among women aged 20–24, but over the 16-year period, 
the peak fertility rate had shifted to women aged 25–35 [11]. The traditional 
Western European pattern, where unintended pregnancies are terminated before 
childbearing is started, can already be seen in Estonian abortion trends. The 
average age of mothers at first births increased from 23.1 in 1996 to 26.3 in 
2011. A comparision of the two periods shows that in 1996–2003, 45.9% and in 
2004–2011, 47.1% of all abortions were obtained by nulliparous women. To 
interpret this small change, it is important to consider that in Western Europe 
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the increase of the age of mothers has lasted for a longer period of time. How-
ever, until today, 90% of women undergoing repeat abortions already had chil-
dren. The finding that the percentage of women undergoing repeat abortions did 
not decrease over the 16 years among women with low educational attainment 
and students indicates an unmet need for contraception among these subgroups. 
Non-Estonians were overrepresented among the women obtaining repeat abor-
tions in 1996 and in 2011 (46% and 38.7%, respectively). However, the de-
crease in repeat abortions among non-Estonians was almost comparable with 
that among Estonians, while the percentage of non-Estonians obtaining third or 
higher-order abortions remained markedly higher than that of Estonians. One 
explanation is that Russian-speaking women tended to prevent unintended 
pregnancies by using less reliable contraceptive methods and, in contrast to 
Estonians, having an abortion increased the risk of them not using contraception 
afterwards. 
Contraceptive patterns before pregnancy termination have been explored in a 
number of studies [97, 191–194] and the variations reflect differences in overall 
contraceptive patterns across countries. The proportion of women who did not 
use any contraception prior to their first, second, third, fourth or subsequent 
abortion, accounted for more than half of the overall population in our study; 
while this increased over the 16-year period, the use of unreliable contraceptive 
methods decreased. Our findings about pre-abortion contraception contrast with 
data from other studies from developed countries where the majority of women 
obtaining their first or repeat abortion failed to use contraception at the time of 
conception [191–195]. This may be due to variations in study design or it may 
reflect different contraceptive patterns, but it is likely to be influenced by a high 
overall abortion rate.  
 
7.2. Contraceptive behaviour and contraceptive counselling 
Despite a notable increase in the use of hormonal contraceptive methods during 
the last two decades, due to the availability of a wide choice of modern contra-
ceptive methods [196], a sizable proportion of women in Estonia still rely on 
contraceptive methods with limited efficacy. In addition to their low efficacy in 
protecting from unintended pregnancy, studies have shown that these methods 
are those used most inconsistently [197]. The current studies found substantial 
differences between the groups of women studied (Estonians and Russians in 
Estonia; and Russians in St. Petersburg) in terms of the prevalence of reported 
use of different contraceptive methods. The unmet need for contraception was 
higher among Russians than Estonians and the largest gap between the two eth-
nic groups occurred in the use of hormonal methods. Already in the early 1990s, 
Anderson et al. hypothesized that a switch from unreliable to reliable contra-
ception among Estonians was more likely to be accomplished than a change 
from abortion to the use of reliable contraception among Russians [198]. In 
Russia, the very low use of hormonal contraceptive methods has not increased 
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during the last decades [63,64]. In comparison between women of the same 
ethnic origin, nonuse of contraceptive methods, e.g., the use of vaginal douch-
ing, was more prevalent in St. Petersburg – almost one in five of the women in 
St. Petersburg did not use contraception – while Russians in Estonia relied more 
on rhythm method and withdrawal than their Estonian counterparts. The high 
proportion of condom use among Russian women in Estonia and in St. Peters-
burg may be partly explained by an increased HIV awareness generated by the 
epidemiological situation in both countries – Estonia and Russia have witnessed 
very similar HIV epidemics with respect to timing, drivers, and magnitude 
[199]. The HIV prevalence is highest in the regions in Estonia where the 
Russian-speaking population predominates. Furthermore, there were more simi-
larities, with respect to the trends in factors associated with unmet need for con-
traception, between Russians in Estonia and in St. Petersburg, than with Esto-
nians. From factors associated with the non-use or use of unreliable contra-
ceptive methods, the unmet need for contraception related to certain socio-
demographic characteristics was a component of high-risk health behavior 
among Estonian women, unlike among the Russian-speaking women in Estonia 
and St. Petersburg. According to the literature, ethnic groups are often asso-
ciated with patterns of contraceptive behaviour [98,199,201]. For Russians, 
there must be other barriers and more complex determinants that influence con-
traceptive choice, which our study did not capture. In addition to women’s 
sociodemographic characteristics and health behaviour, the complex web of 
factors that influence contraceptive choice includes culturally mediated values, 
beliefs, and behaviours regarding contraceptive use and the extent to which 
one’s attitudes, values, beliefs and behaviours change as a result of exposure to 
contextual factors of a particular country [202]. Despite the differences in the 
social and health care systems of the two countries, our investigations indicate 
that Russians in Estonia were more similar to Russians living in St. Petersburg 
than to their Estonian compatriots with respect to their contraceptive behaviour. 
Estonian society is segregated according to ethnicity across a number of dimen-
sions: language, work and geography [30]. Only 41% of ethnic minorities speak 
Estonian at an elementary level or higher and insufficient knowledge of lan-
guage is an important obstacle to interethnic communication [31]. The differ-
ence in the contraceptive patterns of the two ethnic groups in Estonia may be 
due the segregation of Estonian-speaking and Russian-speaking communities, 
including different information sources such as media channels and peers. This 
affects not only patients, but also medical professionals – discrepancies in pat-
terns in the countries surveyed may, to some degree, be explained by the influ-
ence of health care systems. Evidence suggests that contact with health care 
services in connection with pregnancy often triggers a discussion on contra-
ception and increases motivation for the use of effective methods [201]. 
According to study data, this positive influence has been seen only among Esto-
nians – since we found that previous pregnancy and abortion were positively 
associated with the use of reliable contraceptive methods among Estonians. In 
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contrast, the Russian women in Estonia who had undergone abortion had ele-
vated risk for later contraceptive non-use and use of unreliable contraceptive 
methods. Among the respondents in St. Petersburg, the likelihood of using 
reliable contraceptive methods decreased after abortion and after giving birth. 
These findings might be explained by pre- or postabortion and postpartum con-
traceptive counselling in which family planning issues were not sufficiently 
addressed, or because the information provided about reliable contraceptive 
methods did not encourage a change in contraceptive behavior. Perlman and 
McKee described the changes relating to this association in Russia between 
1994 and 2003, and claimed that the discussion of contraceptive issues as part 
of postnatal care had been seen as less important [62]. The steep decline of IUD 
use in Russia, especially in metropolitan areas such as St. Petersburg, might also 
have been influenced by health care providers. According to the literature, 
Russian gynaecologists perceived IUDs as one of the most suitable contra-
ceptive methods in earlier times [64,202]. According to a recent qualitative 
study, Larivaara [203] reported that currently, gynaecologists in St. Petersburg 
considered the IUD to be a problematic choice, even for married women, 
because of fear of infidelity by their husbands and, consequently, the risk of 
STI/HIV. Moreover, counselling approaches that mobilize a patient’s own 
decision and implement her intentions have been associated with successful 
contraceptive adherence [204,205]. Larivaara reported that gynaecologists in St. 
Petersburg seldom discuss women’s wishes or uncertainties during contra-
ceptive counselling [203]. In light of these results, it is interesting that the 
respondents in Estonia and St. Petersburg assessed satisfaction with different 
aspects of contraceptive counselling in health care differently. Satisfaction with 
contraceptive counselling from all service providers in Estonia was comparable 
to the satisfaction reported in Finland but remarkably higher than in St. 
Petersburg where less than half of respondents were satisfied with different 
aspects of the contraceptive counselling they received [190,206]. Despite the 
high acceptance of family medicine as a contraceptive counselling provider in 
Estonia [133], women most frequently prefered and sought contraceptive 
counselling from gynaecologists either in women’s out-patient clinics or private 
practices in Estonia. However, the satisfaction with different aspects of care was 
higher in family doctors practices than in women’s outpatient clinics. Although, 
there is a risk that primary care clinicians have only a short time with patients 
and must address multiple health issues in that window of opportunity [207], 
our study results showed that respondents who had visited a general medical 
practice were more satisfied with the time spent on the visit than those who had 
visited other health care institutions. The high satisfaction level with the service 
provided by family doctors observed in this study shows that the preference of, 
access to and satisfaction with the services of a health care institution are only 
prerequisites for visiting them and other factors may affect the actual visit of a 
patient. One may assume that awareness of the fact that contraception 
counselling falls into the area of competence of a family doctor affects the 
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decision to visit. Although the present study does not allow us to evaluate all 
factors, one can imagine that the high proportion of women visiting 
gynaecologists is both rooted in the traditions and affected by the opportunity to 
have an appointment without a referral from a family doctor.  
The lack of comprehensive contraceptive counselling in Estonia in the 
process of abortion care is a missed opportunity: our survey found that only 
24.0% of Estonian women reported receiving pre- or post-abortion contra-
ceptive counselling [189]. In contrast, in France, 79.6% of women reported that 
they had received information about contraception before or after abortion 
[192]. Although there is no robust evidence that contraceptive counselling 
improves contraceptive adherence [206, 209], there are data to support the fact 
that having contraception choice empowers women to make their own decisions 
and, even if made during the abortion process, it is important in preventing 
unintended pregnancies in the future [204,191,192]. Immediate initiation of any 
contraceptive method after abortion, but especially LARC, has been linked to a 
lower risk of repeat abortion [191].  
 
7.3. Intimate partner violence and selected sexual health oucomes 
Population-based studies with a similar design have shown lower one-year 
physical and sexual IPV prevalence than that found in Estonia: in Eastern Euro-
pean countries such as Poland and the Czech Republic, 3% and 9%, respec-
tively, in New Zealand’s urban areas, 5.2%, in Norway, 5.5% and in Canada, 
3% [14,157,209,210]. There might be several reasons for the high prevalence of 
IPV in Estonia. First, some violence studies do not include threats of violence or 
some levels of violence (pushing, shaking, throwing things), which were the 
most common types of violence reported in our study. Futhermore, the rela-
tively low mean age of respondents (29.4 years) might have influenced the 
overall IPV prevalence. Nevertheless, it should be taken into consideration that 
violence is universally underreported and more likely so in countries with a 
widespread cultural pressure to keep violence “behind closed doors and in the 
family circle” [164,211]. Despite several contextual differences, higher preva-
lence of IPV may be linked to the relatively high prevalence of general violence 
in Estonian society: Estonia has by far the highest incidence of homicides in the 
European Union per 100,000 inhabitants [28].  
Younger women, non-Estonians, women with low educational attainment 
and with economic difficulties were the most vulnerable subgroups for IPV in 
Estonia. IPV was associated with adverse sexual health outcomes such as cont-
raceptive non-use, use of unreliable methods, repeat abortion and condom non-
use, which is in good agreement with other studies [152–156]. 
Only half of the non-pregnant respondents exposed to IPV, compared with 
two thirds who had not been exposed, had used a reliable contraceptive method 
in the recent intercourse, placing many abused women at risk of unintended 
pregnancy. At the same time, a paradoxical gap between contraception use and 
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fertility desire was detected among our study respondents. Likewise, IPV survi-
vors had an elevated risk for a repeat abortion and this association was even 
stronger after adjustment. More IPV survivors reported that they did not use any 
contraceptive method because they were planning a pregnancy. Nevertheless, in 
the hypothetical case of becoming pregnant, they were significantly more likely 
to opt for an abortion rather than have the baby, or expressed their ambivalence 
about the decision. One reason for this discrepancy might be also reproductive 
coercion – male behaviours to promote a pregnancy that is unwanted by the 
women – in an abusive relationship [153,212]. In many studies IPV was asso-
ciated with higher parity [14,153,157]. In Estonia, where abortion services are 
safe and easily accessible, it might be that in the case of unintended pregnancy 
women choose an abortion, which could explain why there was no difference in 
the number of births between IPV exposed women compared to the reference 
group. The high prevalence of physical and sexual violence by intimate partners 
provides evidence for and underlines the importance of IPV as a contributing 
factor in women’s reproductive choices and sexual health outcomes. In Estonia 
where guidelines have not been introduced to govern how medical professionals 
should handle cases of IPV, in case of a repeat induced abortion, STI/HIV, 
dyspareunia, and in cases where there are no other evident causes for symp-
toms, to ask about abuse, help to identify and address women’s needs in violent 
relationships, e.g. find suitable partner-independent contraceptive methods. 
 
7.4. Strenghts and limitations  
The main strengths of the research are:   
1. The validity of the surveillance system, the Estonian Abortion Registry, 
which has national data coverage, a large number of observations and few 
data losses, provides a unique opportunity to utilise a reliable dataset for a 
detailed and comprehensive overview of SH in Estonia. 
2. Our study provided an opportunity to investigate the influence of determi-
nants on abortion, using complete abortion reporting in a unique situation – 
legislation and access to abortion have not changed, but political, economic 
and social changes have been significant during the last two decades in 
Estonia. 
3. The Estonian Women’s Health Survey is based on a probability sample that 
helps to avoid some of the (selection) biases associated with the convenience 
(ie clinic based) samples and thus the estimates derived, e. g., prevalences, 
can be generalized to the population of Estonia. 
4. This was the first time in Estonia when data about unmet need for contra-
ception and sexual health outcomes of IPV have been presented. 
5. The comparability of the research instruments used – the Estonian Women’s 
Health Survey questionnaire and the Reproductive Health and Fertility 
Survey used in St. Petersburg – allows meaningful comparison of the results 
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in Estonia, Russia (and Finland) for assessing contextual (health care and 
socio-political systems) effects on SH. 
 
The main limitations of the research are: 
1. The main limitation of EAR is related to the surveillance system not per-
mitting personal identification and not allowing analysis of associations 
between different socio-demographic factors and abortion.  
2. The Abortion Card offers five options for contraceptive methods. It cannot 
be guaranteed that misclassification of contraceptive methods did not occur. 
For example, despite the availability of transdermal and vaginal hormonal 
contraceptive methods since the early 2000s, the Abortion Card includes 
only “oral hormonal contraception”. It was our assumption and field expe-
rience that under the methods named “other” mostly unreliable contraceptive 
methods such as the rhythm and withdrawal methods and spermicides were 
classified.  
3. Cross-sectional surveys have limitations regarding causality and only pro-
vide evidence of correlations. To decribe the direction of causations, we 
relied on previous evidence from the literature.  
4. Self-reported measures are open to measurement errors such as social desira-
bility and recall biases, especially with life events occurring a long time ago. 
To minimize recall bias we used a standardized well-structured ques-
tionnaire.  
5. A potential major source of error lies in the interpretation of the data. Re-
porting of sexual health behavior is particularly susceptible to contextual 
influences [213]. Observed differences may result from the variation in 
values attached to particular SH factors, and the social desirability governing 
their disclosure. Therefore, anonymous study participation, in order to mini-
mize some of the underreporting and social desirability biases, was used.  
6. Somewhat different sampling methodologies were used in the Estonian 
Women’s Health Survey and in the Reproductive Health and Fertility Survey 
in St. Petersburg. To ensure a meaningful interpretation of the differences 
and similarities across the study groups, an adjusted analysis was performed. 
7. While measuring contraceptive prevalence, division into reliable and un-
reliable contraceptive methods is imprecise since the effectiveness of each 
method is dependent on its correct and consistent use [88]. We do not have 
data on how consistently the methods were used. Therefore, we have used 
the conservative option to identify the contraceptive method used during the 
most recent intercourse at least 12 months before the study as an outcome 
measure. Although we categorized the male condom as a reliable contra-
ceptive method, we are aware that the male condom has been described as 
one of the most discontinued contraceptive methods [214]. The way we cate-
gorised the methods was based on the argument that condoms provide a 
more reliable protection against unwanted pregnancy than alternative 
methods. As unreliable methods (such as rhythm method and withdrawal) 
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are prevalent in Estonia and St. Petersburg, we were particularly interested in 
analysing factors associated with commonly used unreliable contraceptive 
methods in the area. 
8. Respondents were asked about their exposure to physical and sexual IPV in 
the last 12 months preceding the study and not over their lifetime. Therefore, 
we cannot determine the temporal sequence between the timing of sexual 
health outcomes and violence and the results might be biased by the fact that 
some women had been survivors of violence experienced in their childhood. 
Other types of IPV, besides physical and sexual violence, may also influence 
sexual health outcomes but our questionnaire did not capture those. 
However, we believe that our results are reliable providing robust asso-
ciations consistent with data from a large variety of samples between IPV 
and adverse sexual health outcomes [17–19,152–154,157,210].  
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8. CONCLUSIONS 
1. Trends over 16 years indicate a favourable decline of induced abortion and a 
slow but consistent decline of repeat abortion in Estonia, mainly attributed 
by younger cohorts. The high prevelance of repeat abortions reflects the high 
abortion rate in the past and if current trends continue, a rapid decline in re-
peat abortions may be predicted in future years. In respect of repeated abor-
tions, non-Estonians, women with lower educational attainment, students 
and women with children represent particularly vulnerable groups. More 
than half of the women did not use any contraception prior to their first or 
repeat abortions. 
2. The high prevalence of contraception non-use and the use of unreliable 
contraceptive methods in Estonia reflect a high unmet need for family plan-
ning for many women. There were substantial differences between the 
groups of women studied: contraceptive non-use and the use of unreliable 
contraceptive methods among women who were at risk of unintended preg-
nancy was lower among Estonians (27.3%) than to Russians in Estonia 
(39.9%) and in St. Petersburg (42.5%). The clear associations between 
unmet need for contraception with sociodemographic factors and high-risk 
health behaviour among Estonians were not found among Russians in 
Estonia or in St. Petersburg.  
3. Contraceptive counselling for women over 24 years old was provided mainly 
by gynaecologists working in specialized out-patient women’s clinics or pri-
vate practices, the role of family doctors is modest. At least 81% of re-
spondents were satisfied with the friendliness, confidentiality, competence 
and length of the visit from all health care providers. 
4. A substantial proportion of women (one fifth) in Estonia have experienced 
IPV during the last 12 months and this was associated with unmet need for 
contraception and adverse sexual health outcomes: repeat induced abortion; 
lifetime STI/HIV; and dyspareunia. 
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9. MAIN PRACTICAL IMPLICATIONS 
1. The study provides evidence of a strong link between improvements in 
sexual health services, sexuality education and contraception availability 
with decreases in the abortion rate. Any efforts taken to reduce unintended 
pregnancy will reduce the need for repeat abortions. During the process of 
abortion, it is crucial to provide contraceptive counselling as standard care, 
with an emphasis on initiating contraception immediately after abortion and 
encouraging long-acting contraceptive methods. 
2. To decrease the burden of sexual ill-health, mainly unintended pregnancies, 
the problems related to access to evidence-based information about contra-
ception by the Russian ethnic group in Estonia should be addressed at a 
national level with an emphasis on reliable, e. g. hormonal, contraceptive 
methods. 
3. To improve access to contraception and ensure a continued decline in the 
number of abortions, the role of primary care as the provider of contra-
ceptive counselling needs to be increased. There is clearly an opportunity for 
efforts to promote the family medicine system as a provider of contraceptive 
counselling, which requires making a shift in women’s preferences, con-
nected with both traditions and prevailing attitudes towards family planning. 
4. All strategies and interventions aimed at promoting sexual health should 
include prevention of violence against women, e.g., intimate partner violence 
and strengthening of women’s sexual rights. The development and imple-
mentation of a strategy and guidelines for dealing with IPV in the health care 
system, involving different stakeholders, should be urgently addressed in 
Estonia. 
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1. Background information 
 
Date of completing the questionnaire:   _________________ 
 
1. When were you born? 19___ 
 
2. Are you currently (you can choose several alternatives): 
     1     married  
     2     cohabiting 
     3     divorced 
     4     separated 
     5     widow 
     6     single 
 
3. How many times you have been married/cohabiting (cohabiting that later continued 
as marriage is counted as one event)? ________________________ (times) 
 
4. Your citizenship:   ________________________ 
 
5. Your native language:   ________________________ 
 
6. How many persons are living with you (choose one from each row)? 
 yes no 
   1  I live alone 1 2 
   2  spouse 1 2 
   3  co-habiting partner 1 2 
   4  children under the age of 18 1   .............  persons 2 
   5  children over the age of 18 1   .............  persons 2 
   6  daughter’s/son’s spouse, grandchildren 1   .............  persons 2 
   7  my/my co-habiting partner’s parents 1   .............  persons 2 
   8  my/my co-habiting partner’s brothers/sisters 1   .............  persons 2 
   9  my/my co-habiting partner’s other relatives 1   .............  persons 2 
  10 friends, acquantances 1   .............  persons 2 
  11 lodgers 1   .............  persons 2 
  12 others 1   .............  persons 2 
 
7. How many pesons are living together at your home (count yourself also)? 
    __________________   persons 
APPENDIX 
QUESTIONNAIRE 
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 7a. Where do you live?  
     1     Tallinn, Tartu, Pärnu, Kohtla-Järve or Narva 
     2     smaller town/urban settlement 
     3     rural area 
 
8. How many years of education have you had (count school and later education 
years)? 
    __________________   years 
 
9. What is the highest level of education you have completed? 
     1     basic/less 
     2     secondary 
     3     vocational secondary 
     4     vocational higher 
     5     university 
     6     postgraduate degree 
 
10. Are you currently: 
     1     employed  
     2     unemployed 
     3     at home 
     4     pupil/student 
     5     retired, not employed. At what age did you retire?  ____________ years  
     6     other, what _________ 
  
11. What is your current/most recent occupation?      
      ____________________________________ 
    
12. In what occupation have you been employed the longest?  
      ___________________________ 
 
14. What is your monthly average income (monthly salary after deductions and other 
allowances)?  
     ___________________________ EEK 
 
15a. What is your household's average monthly income (monthly salary after 
deductions and other allowances)?  
     1     ___________________________ EEK 
     2     don’t know 
 
15b. How many persons live on this income (yourself inluded)? ______________   
persons 
 
16. Do you have difficulties paying your bills (for housing, electricity, heating etc)?  
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     1     all the time 
     2     often 
     3     sometimes 
     4     rarely 
     5     never 
 
18a. How many rooms does your family have (not counting utility rooms and 
bathrooms)? 
        ______________   rooms 
 
17. Below is a list of various items, which of the following do you have in your 
household? (choose one from each row) 
 yes no 
1   microwave 1 2 
2   video recorder 1 2 
3   television (colour) 1 2 
4   washing machine 1 2 
5   dishwasher 1 2 
6   car 1 2 
7   fridge 1 2 
8   holiday cottage 1 2 
9   video camera  1 2 
10 satellite/cable TV 1 2 
11 telephone 1 2 
12 mobile phone 1 2 
 
 
 
2. Intimate relationships and sexuality 
 
19. At what age did you have your first serious relationship (dating, 
boyfriend/girlfriend – the relationship may/may not have included sexual 
intercourse)? 
     1     I was   ___________ years old 
     2     I haven’t had such a relationship 
 
21b. Have you ever had the following sexual experiences? At what age for the first 
time? 
(choose one from each row) 
 yes, first time at the 
age of 
yes, but I 
don’t 
remember the 
age 
no 
1   masturbation  1   .......... years 2 3 
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 21c. Have you masturbated during the last month? 
     1     yes 
     2     no 
 
20. At what age did you have your first sexual intercourse (vaginal and/or anal)? 
     1     ___________ years old 
     2     I haven’t experienced intercourse 
 
 
The following questions are for those who have had sexual intercourse. If you haven’t 
had sexual intercourse, go to question 25. 
 
21. How old was the partner of your first sexual intercourse? 
     1     ___________  years old 
     2     don’t know 
 
21a. Which of the following statements best describes your first sexual partner? 
     1     I had just met him 
     2     we knew each other earlier, but were not dating 
     3     we had a steady relationship 
 
22. Which contraceptive method did you use in your first sexual intercourse (you can 
choose several alternatives)? 
     1     nothing  
     2     withdrawal (a man does not öet the sperm into the vagina) 
     3     condom 
     4     contraceptive pills 
     4a   contraceptive patch 
     5     emergency contraception (SOS-pills, Postinor 
     6     rhythm method (calculating “risky” days) 
     7     spermicide (vaginal ovules, creams) 
     8     some other method, what (for example vaginal douche etc)? .....................  
     9     don't remember 
 
23. How many sexual intercourse partners have you ever had?   ______________   
partners 
 
24. How many sexual intercourse partners have you had during the last year? 
___________   partners 
 
      2   kissing 1   .......... years 2 3 
      3   petting (touching each other) 1   .......... years 2 3 
      4   oral sex 1   .......... years 2 3 
      5   anal sexual intercourse 1   .......... years 2 3 
      6   vaginal sexual intercourse 1   .......... years 2 3 
8522
30. When did you have the latest sexual intercourse? 
     1     during the last 24 hours 
     2     1–2 days ago 
     3     3–4 days ago 
     4     5–7 days ago 
     5     1–2 weeks ago 
     6     3–4 weeks ago 
     7     1–3 months ago 
     8     4–12 months ago 
     9     1–2 years ago 
    10    3–10 years ago 
    11    more than 10 years ago 
    12    I haven’t had sexual intercourse 
 
30a. How often have you had sexual intercourse during the last 30 days? 
     1     I haven’t had sexual intercourse during the last 30 days 
     2     once 
     3     2–3 times 
     4     once a week 
     5     2–3 times a week 
     6     3–4 tmes a week 
     7     5–6 times a week 
     8     every day/more often 
 
30b. How often have you experienced pain/discomfort during/after sexual intercourse 
in your genitals (vaginal entry, vagina, abdomen)? 
     1     never 
     2     very rarely/few times 
     3     less than half of all occasions  
     4     about half of all occasions 
     5     more than half all occasions 
     6     almost always/always 
     7     I haven’t been able to experience sexual intercourse because of pain/fear of 
pain 
     8     I haven’t experienced sexual intercourse 
 
30c. A release of sexual tension at its peak and the ensuing feeling of pleasure and 
relaxation is called orgasm. How often have you experienced orgasms in your present 
relationship during sexual intercourse, oral sex, petting and other activities? 
     1     always/almost always 
     2     on more than half of all occasions 
     3     on about half of all occasions 
     4     on less than half of all occasions 
     5     vary rarely/few times 
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     6     I haven’t experienced orgasms 
     7     I don’t have a sexual relationship at the moment 
 
30d. Are you satisfied with the frequency of sex (sexual intercourse, oral sex, petting 
etc) in your present steady/couple relationship? 
     1     I wish to have sex considerably more often 
     2     I wish to have sex a bit more often 
     3     I am satisfied with the present frequency 
     4     I wish to have sex a bit less often 
     5     I wish to have sex considerably less often 
     6     I don’t have a steady/couple relationship at the moment 
 
31. Did you consume alcohol before your last sexual intercourse? 
     1     no 
     2     yes, a little 
     3     yes, moderately 
     4     yes, a lot 
     5     I don’t remember 
 
 
All the respondents, please continue from here.  
 
25. Do you have a steady heterosexual relationship (that includes sexual intercourse, 
oral sex/petting) at the moment (you can choose several alternatives)? 
     1     yes, with my spouse 
     2     yes, with my co-habiting partner 
     3     yes, with somebody else 
     4     no, I don’t have a sexual relationship at the moment 
 
27. How are you satisfied with your present sexual relationship? 
     1     very happy 
     2     fairly happy 
     3     not happy, not unhappy 
     4     fairly unhappy 
     5     very unhappy 
     6     I don’t have a sexual relationship at the moment 
 
27a. During the last year have you experienced: 
 
 very often fairly 
often 
fairly 
rarely 
never 
1   lack of sexual desire 1 2 3 4 
2   your partner’s lack of sexual desire  1 2 3 4 
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26. If you are married/cohabiting, then for how long have you been living together? 
(please count also cohabiting before marriage) 
     1     ____________ years and   ____________ months 
     2     I am not living with anybody at the moment 
 
80. Do you think that a woman may refuse sexual intercourse, in the following 
situations (choose one from each row): 
 yes no 
1   the woman has recently given birth 1 0 
2  the woman knows/thinks that her partner/spouse is HIV-
positive/has STDs 1 0 
3   her partner/husband is physically violent 1 0 
4  her partner/husband is drunk  1 0 
5   her partner/husband has a parallel sexual relationship 1 0 
6  the woman is tired 1 0 
7  the woman does not want to have sexual intercourse 1 0 
 
28. Talking about sexual life and contraception with your current partner is: 
     1     very difficult/even impossible 
     2     fairly difficult/complicated  
     3     not very difficult, especially when we have started talking 
     4     very easy 
     5     I have no sexual partner at the moment 
 
29. Have you had parallel sexual relationships during the present 
marriage/cohabitation? 
     1     no 
     2     yes, casual  
     3     yes, permanent  
     4     yes, casual and permanent 
     5     I have no marriage/cohabitation at the moment 
 
32. Sometimes people feel sexual attraction towards the same gender. At the moment 
your sexual attraction is directed: 
     1     only to men 
     2     mostly to men 
     3     equally to men and women 
     4     mostly to women 
     5     only to women 
 
33. Have you had sexual experiences (sexual intercourse, oral sex, petting) with 
someone of the same gender? 
     1     no 
     2     yes, once 
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     3     yes, several times 
 
34. Has anyone tried to induce you to have sexual intercourse with them for money or 
other economic gain? 
     1     no 
     2     yes, but I have refused 
     3     yes, I have agreed once 
     4     yes, I have agreed several times 
 
35. Did your parents discuss sexuality related topics with their children? 
     1     yes, even too much 
     2     yes, sufficiently 
     3     yes, too little 
     4     no, but I would have wished it 
     5     no, but I wouldn’t have wished it 
 
36. Were sexuality related topics discussed at school? 
     1     yes, even too much 
     2     yes, sufficiently 
     3     yes, too little 
     4     no, but I would have wished it 
     5     no, but I wouldn’t have wished it 
 
 
3. Pregnancies and children 
 
37. Are you pregnant at the moment? 
     1     no 
     2     yes 
     3     don’t know 
 
38. Are you breastfeeding at the moment? 
     1     no 
     2     yes, exclusively breastfeeding 
     3     yes, the child gets additional food too 
 
39. How old is the child you are breastfeeding? _______________   months (write 0, 
if you have no child whom you are breastfeeding at the moment) 
 
40. How many times have you been pregnant? (write 0, if you have not been 
pregnant)? 
_____________________ 
 
41.  How
1   miscarriage    _________ (how many)   in  _____________ 
(years) 
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2   ectopic pregnancy   _________ (how many)   in  _____________ 
(years) 3   induced abortion   _________ (how many)   in  
_____________ (years) 
4   childbirth    _________ (how many)   in  _____________ 
(years) 
 
 
The following questions are for those respondents who have given birth. Those who 
have not, go to question 52a. 
 
Children born (children from multiple pregnancies are to be noted separately)  
 1.child 2. 
child 
3. 
child 
4. 
child 
5. 
child 
6. 
child 
7. 
child 
8. 
child 
42. Year of birth  
         
43. The child was born (choose one) 
1 alive 
2 dead 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
44. The child was 
1 a girl 
2 a boy 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
45. Does the child live with you at the moment? 
1 yes 
2 no 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
46. If the child is not living with you at the moment, then when did she/he leave home? (year)? 
         
47. Did you live with the child’s father when the child was born? 
1 yes 
2 no 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
1 
2 
48. Did you live with some other grown-up (a friend, acquaintant, relative) when the child was born? 
1 yes 1 1 1 1 1 1 1 1 
2 no 2 2 2 2 2 2 2 2 
 
49. How long did you breastfeed your last child (count also non-exclusive 
breastfeeding)? 
     1     not at all 
     2     less than 1 month 
     3     ________  months 
     4     I am breastfeeding at the moment 
 
50. Who looked/looks after your last pre-school aged child, when you were/are 
working? (you can choose several alternatives) 
     1     I am not working at the moment, I am/was at home with the child 
     2     the father is/was at home with the child 
     3     grandparents 
     4     other relatives 
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     5     the child goes/went to a state nursery 
     6     the child goes/went to a private nursery 
     7     other, what?__________________________________ 
     8     I have no children 
 
51. In case you have employed a nanny, how did you find him/her? (you can choose 
several alternatives) 
     1     through aquaintances 
     2     through neighbours 
     3     through relatives 
     4     through nanny finding agency 
     5     through an advertisement 
     6     I have not employed a nanny 
 
52. Who looked after you when you were of pre-school age? (you can choose several 
alternatives) 
     1     mother and/or father 
     2     grandparents 
     3     other relatives 
     4     I was at the nursery 
     5     other, what? ______________________________________ 
 
 
4. Use of pregnancy and delivery related health care services  
 
All continue from here. 
 
52a. If you were pregnant now and you would like to continue the pregnancy, which 
health care provider would you contact first (choose only one answer)? 
     1     women’s out-patient clinic 
     2     family doctor 
     3     private gynaecologist  
     4     youth-friendly clinic 
     5     somewhere else, where?_______________ 
     6     I wouldn’t go to a doctor 
     7     I don't know 
 
52b. If you were pregnant now, and you would not like to continue the pregnancy, 
which health care provider would you contact first (choose only one answer)? 
     1     women’s out-patient clinic 
     2     family doctor 
     3     private gynaecologist 
     4     youth-friendly clinic 
     5     somewhere else, where?_______________ 
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     6     I wouldn’t go to a doctor 
     7     I don't know 
 
If you have had no pregnancies, go to question 64. 
 
53. Which health care providers did you use in connection with your last/current 
pregnancy (you can choose several alternatives)? 
     1     women’s out-patient clinic 
     2     family doctor 
     3     private gynaecologist 
     3a   youth-friendly clinic 
     4     other, what?_______________ 
     5     I didn’t use any doctor 
     5a   I don't remember 
 
 
The following questions are about abortion. If you have had abortions, then please 
answer regarding your last abortion. If you have had no abortions, go to question 64. 
 
57a. What contraceptive method were you using when you became pregnant and 
consequently decided to have an abortion? (you can choose several alternatives) 
     1     nothing  
     2     contraceptive pills  
     2a   contraceptive patches 
     3     intrauterine device (“spiral”) 
     4     condom 
     5     spermice (vaginal ovules, cream) 
     6     diaphragm 
     7     contraceptive implants  
     8     sterilisation: own, partner (please underline) 
     9     rhythm method (calculating “risky” days) 
    10    withdrawal (a man does not let the sperm into the vagina) 
    11    vaginal douche (with what agent?) ........................ 
    12    emergency contraception (SOS-pills, Postinor) 
    13    some other method, what? ..................... 
    14    don't remember 
 
58. Where was the abortion induced? 
     2     hospital gynaecology ward/day care) 
     4     private clinic/practice 
     5     somewhere else, where? _____________________________________ 
 
59. Did you pay for the abortion? 
     1     yes, the official sum 
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     1     yes, non-officially, how much? (please specify the 
amount)______________________ 
     2     yes, the official sum and also non-officially, how much? (please clarify the 
amount of  
           money)   ______________________________________ 
     3     I payed with other means, please specify 
__________________________________ 
     4     no, I didn’t pay 
 
59a. Indicate your satisfaction with the amount of information you received from the 
doctor/nurse before the abortion about the following topics (choose one from each 
row): 
 very 
satisfied 
fairly 
satisfied 
fairly 
unsatisfied 
very 
unsatisfied 
1  abortion procedure 1 2 3 4 
2  possible psychological influences 1 2 3 4 
3  possible medical risks/complications related 
to abortion 
1 2 3 4 
 
60a. Did you receive counselling about contraception before/after the abortion? 
     1     yes 
     2     no 
     3     don’t remember 
 
61. Were you satisfied with the way you were treated in the hospital/clinic during the 
abortion? 
     1     very satisfied 
     2     fairly satisfied 
     3     fairly dissatisfied 
     4     very dissatisfied 
     5     cannot say 
I wish to comment: 
_____________________________________________________________________
_____________________________________________________________________
__________ 
 
62. What were the reasons in your decision to have an abortion? (you can choose 
several alternatives) 
     1     I was not ready to take the responsibility for raising a child 
     2     I didn’t want to raise a child alone 
     3     I didn’t want to jeopardise my relationship/family unity with the birth of 
another child  
     4     my couple relationship was unstable/problematic 
     5     I didn’t want to have a child with this particular partner 
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     6     I gave up this pregnancy because of pressure from my partner/parents 
(underline) 
     7     for economic reasons 
     8     my living space (flat) was too small and I was not able to improve my living 
conditions 
     9     I was in the middle of my studies 
    10    work didn’t allow it 
    11    I was not mature enough to be a mother 
    12    I was too young 
    13    I had nobody who would have helped me to take care of the child 
    14    I didn’t have time for the child 
    15    other, please 
specify___________________________________________________ 
 
63. Did you discuss the abortion beforehand with your partner? 
     1     no  
     2     yes 
 
63a. Where did you go for a follow-up visit during one month after the abortion? 
(you can choose several alternatives) 
     1     I didn't go for the follow-up visit, why?_______________ 
     2     hospital, where the abortion was induced 
     3     policlinic, women’s outpatient clinic 
     4     private clinic 
     5     somewhere else, where?_______________ 
     6     don’t remember 
 
All continue from here. 
 
64. Have you ever had difficulties in getting pregnant, although you were having  
regular sexual intercourse during one year? 
     1     yes 
     2     no (go to question 66b) 
  
65. Have you been investigated and/or treated for possible infertility? 
     1     yes, most recently in  ______________ (year) 
     2     no (go to question 66) 
 
65a. What treatments have you received for infertility? (choose one from each row) 
 yes no 
1  hormonal treatment 1 2 
2  insemination (IUI) = sperm is placed in the uterus 1 2 
3  in vitro fertilization (IVF) 1 2 
4  IVF with microinjection (ICSI) = sperm is placed into the egg cell  1 2 
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during IVF 
5  IVF with cryopreserved embryos (FET) 1 2 
6  other treatment (incl all alternative treatments), 
what?_________________________________ 
1 2 
 
66. If you haven't sought medical help for your infertility or you have discontinued 
investigations, what is the reason for this?(you can choose several alternatives) 
     1     I still want to wait and try to become pregnant naturally 
     2     I don't want medical interference  
     3     I haven't been aware what treatments for infertility are available 
     4     I am too old to get treatment 
     5     investigations are too expensive 
     6     hospital and infertility clinics are too far away 
     8     it is difficult to get an appointment to the specialist 
     9     my partner does not want to come for the investigations 
    10    my relationship came to an end 
    11    I was ashamed to approach a specialist with that problem 
     7     other reason, what? _______________________________________________ 
 
66a. Have you been satisfied with the information you received during infertility 
investigations and treatment about the following topics? (choose one from each row) 
 satisfie
d 
fairly 
satisfie
d 
fairly 
unsatisfi
ed 
unsatisfi
ed 
1  infertility investigations and treatment 1 2 3 4 
2  psychological effects of infertility 1 2 3 4 
3  possible medical risks related to investigations and 
treatment 
1 2 3 4 
 
 
All continue from here. 
 
66b. If you became preganant now, what would be your most probable decision? 
     1     I would have a baby 
     2     I would have an abortion 
     3     don’t know 
 
67. At what age did you have your first menstruation? _____________ years 
 
68. Have you had the following sexually transmitted diseases?  (choose one from each 
row) 
 yes no don’t 
know 
1  genital herpes 1 3 2 
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2  papillomavirus/condylomas 1 3 2 
3  chlamydiosis 1 3 2 
5  gonorrhoea 1 3 2 
6  syphilis 1 3 2 
7  HIV/AIDS 
9
3 2 
8  trichomoniasis 1 3 2 
10 other genital tract infection (bacterial vaginosis,    
    thrush) 
1 3 2 
 
 
5. Contraception 
 
If you have not experienced sexual intercourse, go to question 78. 
 
70. Which contraceptive method did you use during your last sexual intercourse? 
(you can choose several alternatives) 
     1     we did not use any contraceptive method as we are trying to conceive 
     1a   we don't need/use any contraceptive method as we are not able to conceive 
     2     contraceptive pills 
     2a   contraceptive patch 
     3     intrauterine device (“spiral”) 
     4     condom 
     5     spermicide (vaginal ovules, creams) 
     6     diaphragm  
     7     contraceptive implants 
     8     sterilisation: own, partner (please underline) 
     9     rhythm method (calculating “risky” days) 
    10    withdrawal (a man does not let the sperm into the vagina) 
    11    vaginal douche (with what agent?) ........................ 
    12    emergency contraception (SOS-pills, Postinor) 
    13    some other method, what? ..................... 
  
71. Who decided on using contraception in your last sexual intercourse? 
     1     I 
     2     my partner 
     3     we both 
     4     someone else, who? ____________________________ 
     5     don’t know, don’t rememberwe didn’t use contraception during our last sexual 
intercourse 
 
If you used a contraceptive method during your last sexual intercourse, go to question 
73. 
 
72. If you did not use a contraceptive method during your last sexual intercourse, 
what was the reason? (choose a maximum of three answers) 
6
     1     I was not aware of available contraceptive methods 
     2     I didn’t want to use contraception 
     3     my partner didn’t want/didn’t allow me to use contraception 
     4     we do not need contraception as we are planning a pregnancy 
     5     we do not use contraception for religious reasons 
     6     we do not need contraception as I am pregnant at the moment 
     7     we do not need contraception as I / my partner is infertile 
     8     other reason, 
what?____________________________________________________ 
 
72a. If you did not use a contraceptive method during your last sexual intercourse, 
where there any additional reasons? (choose one from each row) 
 yes no 
   1  I am afraid of the side effects of contraceptive methods 1 2 
   2  contraceptive methods are too expensive 1 2 
   3  it is difficult to obtain contraceptive methods 1 2 
 
73. If you use/have used condoms, then why? (choose only one answer) 
     1     mainly for avoiding pregnancy 
     2     mainly for avoiding sexually transmitted diseases 
     3     equally for avoiding pregnancy and sexually transmitted diseases 
     4     other, please specify ____________________________ 
     5     we haven’t used condoms 
 
74. Have you ever used contraceptive pills? 
     1     yes 
     2     no 
 
74a. If you have formerly used pills, but stopped, then why? (you can choose several 
alternatives) 
     1     I didn’t need contraception any more 
     2     I was afraid of possible side effects, please specify? 
__________________________ 
     3     I experienced side effects and/or contraindications, please specify? 
_____________ 
     4     for economic reasons 
     5     a doctor/nurse recommended me to stop/have a break 
     6     other, please specify ____________________________ 
  
76. Are you satisfied with your current contraceptive method? 
     1     very satisfied 
     2     fairly satisfied 
     3     fairly dissatisfied 
     4     very dissatisfied 
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     5     I don't use contraception at the moment 
 
77. Have the costs affected your decisions concerning the use of contraception during 
the last year? (Choose all that apply 
     1     no 
     2     because of the cost, I haven't used the method I would have liked to 
     3     I have not been able to visit a doctor as often as I consider necessary 
     4     I have not been able to have all the necessary laboratory tests 
     5     I don't know 
     6     other, what ?______________________________________________ 
     7     I haven't needed contraception during last year 
 
 
All continue from here. 
 
78. When did you last visit a health care service for contraceptive 
counselling/prescription?  
     1     less than 6 months ago 
     2     6–12 months ago 
     3     more than one year but less than 2 years ago 
     4     2–5 years ago 
     5     more than 5 years ago 
     6     I haven’t visited a health care institution for that purpose 
     7     don't remember 
 
78a. Which health care service did you last visit in order to receive contraceptive 
counselling/prescription? 
     1     women’s outpatient  clinic 
     2     family doctor 
     3     private gynaecology clinic 
     4     youth-friendly clinic 
     5     elsewhere, where?_______________ 
     6     I haven’t visited a health care service for that purpose 
     7     don’t remember 
 
79. Evaluate how well the following aspects of care were carried out during your last 
visit for contraception? (choose one from each row)  
 very 
dissatisfied 
fairly 
dissatisfied 
fairly 
satisfied 
very 
satisfied 
don’t 
remembe
r 
1  friendliness 1 2 3 4 5 
2  competence 1 2 3 4 5 
3  reliability 1 2 3 4 5 
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4  length of the visit 1 2 3 4 5 
 
79a. Have some of the following impeded you in visiting a doctor for contraception 
during the last year (you can choose several alternatives)? 
     1     it was difficult to get an appointment 
     2     doctor is far away/bad transportation connections 
     3     it is not easy to get an appointment to a gynaecologist (specialist)  
     4     I didn't know where to find a good gynecologist 
     5     I would like to visit someone else than my own doctor 
     6     previous negative experiences 
     7     I was ashamed to visit a gynaecologist 
     8     I was afraid of the gynecological examination 
     9     other reasons, what? _____________________________________ 
    10    I have not had any problems with such visits 
    11    I haven’t needed any physician services regarding contraception 
 
103. Where would you prefer to go for a contraceptive visit/prescription? (choose 
only one from each part) 
 
A. 
     1     the same doctor whom I visit for other health reasons 
     2     some other doctor 
     3     doesn't matter if I know the doctor or not 
     4     I cannot say 
 
B   
     1     gynaecologist 
     2     family doctor 
     3     doesn't matter 
     4     cannot say  
 
C   
     1     male doctor 
     2     female doctor 
     3     doesn't matter 
     4     cannot say 
 
D   
     1     private doctor 
     2     family doctor centre 
     3     women’s outpatient clinic 
     3a   youth friendly clinicdoesn't matter 
     4     cannot say 
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75. Have you heard about morning-after pills (Postinor) before completing this 
questionnaire? 
     1     yes 
     2     no 
 
75a. Have you ever used morning-after pills? 
     1     no 
     2     yes,   _____________ times 
 
81. It has been said that men participate too little in making contraceptive choices and 
during childbirth. In your opinion, should men's role/involvement be changed in 
regard to: (choose one alternative from each line) 
 
 increased a 
lot 
somewhat 
increased 
no change 
necessary 
decreased 
 
cannot say 
1  Responsibility for contraception? 
 1 2 3 4 5 
2  Responsibility for costs of contraception? 
 1 2 3 4 5 
3  Visiting maternity services during pregnancy? 
 1 2 3 4 5 
4  Participation in childbirth? 
 1 2 3 4 5 
5  Responsibility in deciding about induced abortion? 
 1 2 3 4 5 
 
 
6. Reproductive plans 
 
82. If you think in general terms, not from your personal point of view, then: 
     1     What is the ideal number of children in a family nowadays?________ 
child/children 
     1     How long is the ideal spacing between children?  ________ years 
     3     What is the ideal age for having a first baby? 
 a) for a woman   ________ years 
 b) for a man  ________ years 
 
83. How many children would you yourself like to have? _______ child/children 
 
 
If you have a child/children, go to question 86. 
  
84. If you do not have a child, then why haven’t you had one? (you can choose 
several alternatives) 
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     1     I haven’t met such partner with whom I would like/ would have liked to have 
a child 
     2     we have tried to conceive, but have not been successful so far 
     3     I wish to finish my studies first 
     4     my partner wishes to finish his studies first 
     5     I wish to get stable work first 
     6     my partner wishes to get stable work first 
     7     I wish to go on with my career 
     8     I feel that I am not mature enough to take responsibility for a child 
     9     I feel that my partner is not mature enogh to take responsibility for a child 
    10    for economic reasons 
    11    I would like to have stable living conditions first 
    12    there are problems in our relationship 
    13    other, what?____________ 
    14    don’t know 
 
85. If you chose more than two answers to the previous question, please specify which 
answer is the most important for you? 
     1     answer number ____________ 
     2     don’t know 
 
From here all continue. 
86. Are you planning to have a child/children in the future? 
     1     no (go to guestion 90) 
     2     don't know, I haven’t decided (go to guestion 90) 
     3     yes, I wish to have ............... (number)  children 
     4     I am pregnant at the moment, in the future I wish to have another ....(number)  
children 
  
87. When do you wish to have your first/next child?  
after ______ years 
 
88. Why do you wish to have one more child/more children? (you can choose several 
alternatives) 
     1     the child/children we have need a brother/sister 
     2     I wish to have a daughter 
     3     I wish to have a son 
     4     I enjoy watching a child’s development 
     5     life continues only through children 
     6     my partner wishes to have more children 
     7     I wish to have a child with my current/new partner 
     8     a common child is a sign of mutual love 
     9     I desire a little baby/have “baby fever” 
    10    more children are needed to preserve the Estonian nation 
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    11    I do not want to be alone when I am old 
    12    children are of help doing domestic work 
    13    I wish to take care of a child and love him/her 
    14    I want to have a big family 
    15    I want (once more) to experience a delivery 
    16    I wish to experience motherhood 
    17    a human being has to have as many children as God gives 
    18    a child gives you a goal in life, to live and work 
    19    children bring variety to one’s life 
    20    other, what? __________________________________________________ 
    21    don’t know 
 
89. If you chose more than two answers to the previous question, please specify which 
answer is the most important for you? 
     1     answer number ____________ 
     2     don’t know 
 
Questions 90-93 are for those who do not want to have more children/have not 
decided yet.  
 
90. If you do not want to have (more) children/are unsure, then why? (you can choose 
several alternatives) 
     1     I am not married/cohabiting with anyone, there is no suitable father for a child 
     2     my partner does not want (more) children 
     3     my partner does not take part in domestic work and looking after children as 
much as I  
            would expect 
     4     there are problems in our relationship 
     5     I wish to spend more time with my partner and shared hobbies 
     6     I probably cannot have children  
     7     if I have a child I cannot continue working/studying (as much as I do now) 
     8     I am afraid that in case of a new child I will lack time and attention for my 
older  
            child/children 
     9     I am afraid that life would be too hard 
    10    I do not want to be engaged with little children (any more) 
    11    I do not want to be pregnant and/or give birth (any more) 
    12    I think I am too old for having babies 
    13    I want to dedicate myself to other things I am interested in 
    14    I/we do not have enough money for children 
    15    our living conditions are not suitable for a bigger family and we are not able to 
improve  
            them  
    16    I/my partner do not have stable employment 
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    17    the possibilities of help in looking after the child are unstable 
    18    society does not support families with children 
    19    the world is overpopulated 
    20    my/my family’s health problem prevents me having a child  
    21    other, what? _______________________________ 
    22    don’t know 
 
91. If you chose more than two answers to the previous question, please specify which 
answer is the most important for you? 
     1     answer number ____________ 
     2     don’t know 
 
92. Are there any possible changes in society/in your private life that can affect your 
decision about having (more) children? (you can choose several alternatives) 
     1     improvement/stabilisation of personal economic conditions 
     2     moving to a larger home 
     3     sufficient possibilities to be at home with a child/children 
     4     sufficient opportunities for acceptable babysitting arrangements 
     5     an increase in financial assistence to families with children 
     6     the availability of a good and trustworthy babysitter (e.g. near home) 
     7     women’s and men’s equal participation in domestic work 
     8     certainty that your job will still be there after you have given birth 
     9     working hours are shorter and more flexible 
    10    Estonia becames a safer place to live 
    11    Estonia’s pouplation decreases to a critical level 
    12    people are more friendly towards children 
    13    solution of global problems (pollution, nuclear weapons etc) 
    14    I am not able to have children 
    15    other, what?___________________________________________ 
 
93. If you chose more than two answers to the previous question, please secify which 
answer is the most important for you? 
     1     answer number ____________ 
     2     don’t know 
 
 
7. Health and use of health care services 
 
94. How do you rate your current level of health? 
     1     very good 
     2     good 
     3     neither good nor bad 
     4     bad 
     5     very bad 
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 95. How do you rate your quality of life? 
     1     very good 
     2     good 
     3     average 
     4     bad 
     5     very bad 
     6     don’t know 
 
96. Do you have some long-term illness, physical disability or handicap, injury or 
pain, that affects your functioning or ability to work) 
     1     no 
     2     yes, what?________________________________________________ 
  
97. How tall are you?  _______ cm 
 
98. How much do you weigh (not being pregnant)? _______ kg 
 
99. Have you visited a doctor during the last 12 months because of a disease (and also 
pregnancy and delivery)? Do not count hospitalisations. 
     1     no 
     2     yes, _______ times 
 
100. Have you been hospitalised during the last 12 months because of a disease (and 
also pregnancy and delivery)?   
     1     no 
     2     yes, _______ times 
 
101. At what age did you firs visit a gynaecologist? 
     1     __________ years 
     2     I haven’t visited a gynaecologist      
     3     don’t remember 
 
101a. How do you rate your first visit to a gynaecologist? 
     1     very positive experience 
     2     fairly positive experience 
     3     fairly negative experience 
     4     very negative experience 
     5     don’t know 
I wish to comment: 
_____________________________________________________________________
_____________________________________________________________________
__________ 
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102. Have you undergone any of the following examinations? (please answer all the 
questions by choosing the most appropriate number on each row):  
 
 
 
During last 5 
years 
Earlier Never Don’y 
know, 
remembe
r 
1  mammography (breast X-ray examination) 1 2 3 4 
2  breast examination (doctor) 1 2 3 4 
3  breast ultrasound examination 1 2 3 4 
4  PAP-smear (oncocytology) 1 2 3 4 
5  gynecological examination 1 2 3 4 
 
104. Have you been smoking at least one sigarette, sigar or pipe per day during one 
year? 
     1     no 
     2     yes formerly, but not now 
     3     I smoke daily 
     4     I smoke periodically 
 
105. How often  do you drink sufficient alcohol to get drunk? 
     1     daily 
     2     few times a week 
     3     once a week 
     4     twice a month 
     5     once a month 
     6     once every two months 
     7     3–4 times a year 
     8     once a year/less 
     9     never 
 
106. Have you ever used drugs? 
     1     no 
     2     yes, intravenous 
     3     yes, other 
 
107. Have you experienced the following situations during the last year (you can 
choose several alternatives)  
 by partner  by husband 
(marriage or 
cohabiting) 
by 
someone 
else 
1  threatened with violence 1 2 3 
2  pushed, shaken, had something thrown at you 1 2 3 
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3   hit with something that caused/could have 
caused physical injury  
1 2 3 
4  threatened with a knife/other object 1 2 3 
5  physically forced to have sexual intercourse  1 2 3 
6  threatened/frightened into having sexual 
intercourse 
1 2 3 
7   forced against your will to participate in other 
sexual acts 
1 2 3 
8  no 0 
 
108. If you have been quarreling with your partner during the last year, how often did 
you have... (mark x) 
 no 1-2 3-5 6-10 11-20 > 20 
1  bruises/pain        
2  wounds/broken bones       
3  injuries that needed 
medical attention  
      
4  we have not quarreled  
 
109. Have you talked to anyone about the violence? 
     1     no 
     2     yes, who? ___________________________ 
     3     I haven’t experienced violence  
 
Thank you! 
If you wish to comment: 
_____________________________________________________________________ 
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SUMMARY IN ESTONIAN 
Naiste seksuaaltervist ja  
reproduktiivseid valikuid mõjutavad tegurid Eestis 
Maailma Terviseorganisatsioon defineerib seksuaaltervist (ST) täieliku kehalise, 
emotsionaalse, vaimse ja sotsiaalse heaolu seisundina, mis on seotud seksuaal-
susega [1]. Mõiste annab edasi ST positiivse sisu, mis nõuab austavat suhtumist 
seksuaalsusesse ja rõhutab vajadust austada kõigi inimeste seksuaalõigusi. Hea 
ST annab võimaluse soovitud reproduktiivseteks valikuteks, sealhulgas 
otsutada, kas, millal ja kui palju saada lapsi, ning muuta elu ja isiklikke suhteid 
paremaks.  
ST mõjurid on mitmetahulised ja üksteisega seotud. Bioloogiline sugu ja 
sotsiaaldemograafilised tegurid mõjutavad ST olulisel määral. Siiski, võrreldes 
teiste tervise valdkondadega, on ST puhul märksa olulisemad ka välistegurid (nt 
poliitilised, õiguslikud, kultuurilised, ideoloogilised ja religiooniga seotud 
mõjurid), mille üle inimestel endil on kontroll piiratud või see puudub.  
ST kõigile inimestele oluline läbi kogu nende elukaare, kuid mõjutab bio-
loogiliste ja sotsiaalsete eripärade tõttu naisi enam kui mehi. Maailmas moodus-
tavad viljakas eas naiste enneaegsest haigestumusest ja suremusest kolmaniku 
(32%) STga seotud põhjused [7]. Ehkki haigestumus ja suremus on peamiselt 
seotud raseduse ja sünnitusega, siis on ka teisi põhjuseid – naiste ebavõrdne 
vastutus rasedusest hoidumise ja viljatuse eest; seksuaalsel teel levivate infekt-
sioonide, sh HIV tagajärjed naistele; naistevastase vägivalla mõju STle. 
Eestis, kus heatasemeline sünnitusabi on riiklikult tagatud – seksuaalharidus 
ja -tervise teenused ning rasestumisvastased meetodid on hästi kättesaadavad, 
abort on legaalne ja turvaline – on ST pigem mõjutatud sotsiaalsest ja soolisest 
ebavõrdsusest [9].  
 
Uurimistöö keskendub viljaks eas naiste seksuaaltervisele ja reproduktiivsete 
valikutele rõhuga indutseeritud abordile, soovimatust rasedusest hoidumisele ja 
paarisuhte vägivallale.  
 
Abortide kohta on alates 1996. aastast süsteemselt andmeid kogutud Eesti 
Abordiregistrisse. Selle perioodi jooksul on toimunud abortiivuskordajate 
märkimisväärne pidev langus. Vaatamata positiivsele suundumusele on kordu-
sabortide tase Eestis kaks korda suurem võrreldes sarnast registreerimist kasu-
tavate riikidega [12]. Meid huvitas kordusabortide arvu trend viimase 15 aasta 
jooksul. Arvestades ühiskonna sotsiaal-majandusliku kihistumist, soovisime 
teada saada, kuidas see on mõjutanud abordivajadust erinevates sotsiaal-
majanduslikes rühmades.  
Abort on enamasti seotud kontratseptsiooni mittekasutamisega või kasuta-
mise ebaõnnestumisega. Eestis ei ole süsteemseid andmeid kontratseptsiooni-
meetodite kasutamise ega selle mõjurite kohta. On teada, et Eestis elavate eest-
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laste ja mitte-eestlaste reproduktiivsed valikud erinevad – läbi aastate on eest-
laste sündimuskordajad olnud kõrgemad ja abortiivsuskordajad madalamad 
[11]. Meie hüpotees oli, et eestlaste ja mitte-eestlaste kontratseptsiooni kasuta-
mise muster ning seda mõjutavad tegurid on erinevad. Selleks, et saada infot ka 
kontratseptsiooni välismõjurite kohta, võrdlesime kahte rahvust erisugustes 
sotsiaalpoliitilistes oludes Eestis ja Venemaal (Peterburis). 
Kontratseptsioon, vaadates naiste seisukohalt, on üks nähtavamaid ST vaja-
dusi – kaitset soovimatu raseduse eest vajab enamik viljaka eluperioodi kestel ja 
vajadused on kiiresti muutuvad. Seetõttu on eri kontratseptsioonimeetodite ja 
sellealase nõustamise kättesaadavus ning kvaliteet olulised. Teadaolevalt riiki-
des, kus esmatasandi arstiabi on peamine rasestumisvastase nõustamise pak-
kuja, kasutatakse rohkem tõhusaid rasestumisvastaseid meetodeid ja abor-
tiivsuskordajad on madalad [130]. Eestis on viimase kahe kümnendi jooksul 
lisaks naistearsti teenusele tulnud juurde uusi võimalusi rasestumisvastase 
nõuande saamiseks tervishoiusüsteemis: noorte nõustamiskeskused, eramedit-
siin ja esmatasandi peremeditsiin. Oma uurimistöös me soovisime teada, milline 
on eri tervishoiuasutuste roll ja patsientide hinnangud selle kvaliteedile.  
ST on mõjutatud oluliselt mõjutatud paarisuhte poolt. Paarisuhtevägivald 
igasugune füüsilise agressiooni, seksuaalse sunduse, psühholoogilise vägivalla 
ja kontrolliva käitumise akt, mis põhjustab füüsilist, seksuaalset või psühho-
loogilist kahju [134]. Paarisuhtevägivald võib toimuda nii praeguste kui ka 
endiste elukaaslaste, abikaasade või intiimpartnerite vahel. Paarisuhtevägivald 
on seotud oluliste tervisekahjudega, sealhulgas lühi- ja pikaajaliste ST häiretega 
[15–23]. 
Paarisuhtevägivald on Eestis tähelepanu pälvinud alles hiljuti ja seda pee-
takse privaatseks teemaks, mitte sotsiaalmajanduslikuks probleemiks või ter-
visehäirete oluliseks riskiteguriks [24]. Paarisuhtevägivalda ei käsitle vajalikul 
määral eraldi Eesti õigusaktid ja sellega ei tegele süsteemselt tervishoiusüsteem 
[24,26]. Kuna ametikus statistikas kajastub paarisuhtevägivallast vaid väike osa 
ja olemaolevate uuringute andmeid paarisuhtevägivalla ulatuse kohta leidub 
vähe, huvitas meid paarisuhtevägivalla levimus ning selle mõju naiste seksuaal-
tervisele Eestis.  
 
Eesmärgid 
Töö üldeesmärk oli välja selgitada naiste seksuaaltervise mõjurid ja reproduk-
tiivsed valikud Eestis. 
Töö alaeesmärgid olid  
1. Kirjeldada indutseeritud abortide ajatrende rõhuasetusega kordusabortidega 
seotud sotsiaaldemograafilistele tunnustele ja kontratseptsiooni kasutamisele 
enne aborti (artikkel I).  
2. Mõõta kontratseptsioonimeetodite levimust ja hinnata, millised sotsiaal-
demograafilised, reproduktiivanamneesi ning riskeeriva seksuaalse- ja 
tervisekäitumisega seotud tegurid mõjutavad kontratseptsiooni kasutamist eri 
rahvustel Eestis ja Peterburis; Venemaal (artikkel II). 
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3. Uurida, milliseid tervishoiuasutusi eelistavad ja kuidas on rahul kontratsept-
sioonialase nõustamisega erinevate külgedega üle 24aastased naised (artikkel 
III). 
4. Analüüsida paarisuhte vägivalla levimust ning selle mõju reproduktiivsetele 
valikutele ja seksuaaltervisele (artikkel IV). 
 
Andmed ja metoodika 
Uurimistöö andmed pärinevad Eesti Meditsiinilisest Sünni- ja Abordiregistrist 
(I) ning kahest läbilõikelisest seksuaaltervise uuringust, mis viidi läbi Eestis (II–
IV) ja Peterburis 2003–2005 (II). 
Eesti Meditsiiniline Sünniregister loodi 1991. aastal ja Abordiregister 1995. 
aastal. Kõik Eesti territooriumil rasedusi katkestanud või katkenud rasedusega 
naistele arstiabi osutanud tervishoiuasutused ja eraarstid on kohustatud täitma 
anonüümse abordiregistri kaardi ning saatma andmed registrisse. Registris toi-
mub: andmete kodeerimine, sisestamine, kontrollimine ja täpsustamine koos-
töös tervishoiuasutuste ning rahvastikuregistriga, samuti standardtöötlus, pärin-
gutele vastamine, andmete säilitamine ja paberdokumentide arhiivimine.  
Esitasime andmed aastate kaupa sündimuse erikordaja (elusündide arv 1000 
15–49aastase naise kohta), abortiivsuskordaja (abortide arv 1000 15–49aastase 
naise kohta), abortiivsuse vanuskordaja (abortide arv vanusrühmiti naiste aasta-
keskmise arvu kohta) ja abordimäära (abortide arv 100 elussünni kohta) aastatel 
1996–2011. Analüüsisime ainult indutseeritud aborte, kordusabortide ana-
lüüsiks arvasime välja need indutseeritud abordid, mis olid tehtud meditsiini-
listel näidustustel. Võrdlesime kordusaborte kahel perioodil: 1996–2003 (105, 
938) ja 2004–2011 (38, 132). Käsitlesime abortide osakaalu teise, kolmanda, 
neljanda ja enam abordi korral. Registrist kättesaadavad taustatunnused olid 
vanus, haridus, perekonnaseis, rahvus, tegevusala ja eelnevate sünnituste arv. 
Arvutasime kordusabortide osakaalu erinevuse perioodi taustategurite lõikes ja 
selle protsendilise erinevuse koos 95% usaldusvahemikega iga taustatunnuse 
alarühma suhtes. Võrdlesime kordusabortide osakaalu 15–49aastaste naiste 
osakaaluga rahvastikus samas vanusrühmas kahel uuringuperioodil. Esmas- ja 
kordusabortide korral analüüsisime rasestumisvastaste meetodite kasutamist 
vahetult enne aborti kasutatud rasestumisvastase meetodi kohta (“pillid; emaka-
sisene vahend; kondoom: muu; ei kasutanud; pole andmeid”). Analüüsisime 
kordusabortide osakaalu erinevusi eestlastel ja mitte-eestlastel. 
Kahes läbilõikelises uuringus Eestis ja Peterburis kasutati sarnast valik-
vastustega küsimustikku, mis koostati rahvusvahelise teaduskonsortsiumi juhi-
tud projekti “Reproductive Health and Fertility Patterns – A Comparative 
Approach” raames. Paljude küsimuste puhul lähtuti varasematest Soome uurin-
gutest ja kasutati neis esinenud küsimusi [184–188]. Tartu Ülikooli naistekliinik 
korraldas anonüümse postiküsitluse, mille metoodikat on üksikasjalikult kirjel-
datud uurimisaruandes [189]. Lühidalt, Rahvastikuregistri alusel moodustati 
vanuse järgi kihitatud juhuvalim suurusega 5190 naist vanuserühmades 16–25, 
26–35 ja 36–44 a. Neile saadeti kas eesti- või venekeelne küsimustik, mis sisaldas 
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128 valikvastusega küsimust. Mittevastanutele saadeti küsimustik teistkordselt 
10 nädala pärast. Vastamismääraks kujunes 53,8%. Uuringul on Tartu Ülikooli 
Inimuuringute Eetikakomitee luba.  
Peterburis saadi uuritavate andmed juhuvalimina politsei jaoskonna andme-
baasist kahe Peterburi linnaosa ja kolme ambulatoorset naistearstiteenust 
pakkuva raviasutuse kohta. Valimisse kuulus 2510 naist ja valim kihitati 
vanuserühma (18–25, 26–35 ja 36–44 a) ja raviasutuse järgi. Küsimustikule tuli 
vastata sobivas raviasutuses, kus samaaegselt pakuti naistearsti konsultatsiooni. 
Mitteilmunutele helistati või viidi küsimustik koju. Vastamismäär oli 66,7%. 
Uuringul on Peterburi Uuringute Akadeemia Eetikakomitee luba. 
Kontratseptsioonimeetodite levimust ja kasutamise mõjureid uurisime kolme 
rahvastikurühma lõikes eraldi: eesti emakeelega vastajad Eestis (1189), vene 
emakeelega vastajad Eestis (491) ja Peterburis (768). Uuringusse kaasati 
viimase 12 kuu jooksul seksuaalvahekorra kogemusega 20–44-aastased naised, 
kes ei soovinud rasestuda. Analüüsisime rasestumisvastaste meetodite kasuta-
mist vanuserühmiti (20–24, 25–34 ja 35–44 a) kohandades tulemused Euroopa 
standartrahvastikule. Kasutatud rasestumisvastased meetodid kui sõltuva tun-
nuse jaotasime nende efektiivsuse alusel [88] kahte rühma: tõhus d (hormo-
naalsed meetodid, emakasisesed meetodid, steriliseerimine, kondoom) ja eba-
tõhusad meetodid (spermitsiidid, rütmimeetod, katkestatud suguühe). Viimasele 
rühmale lisasime tupeloputuse ja rasestumisvastase meetodi mittekasutamise. 
Hindasime ebatõhusate rasestumisvastaste meetodite ja kontratseptsiooni mitte-
kasutamise seoseid taustateguritega: vanus, haridus, perekonnaseis, majanduslik 
toimetulek, eelnenud sünnituse ja/või abordiga lõppenud rasedused ja suitseta-
mine. Moodustasime liittunnuse, mis iseloomustas seksuaalset riskikäitumist.  
Kontratseptsioonialase nõustamise hindamine artiklis III hõlmab 25–44 
aastaseid naisi, kes olid pöördunud tervishoiuasutusse rasestumisvastase 
nõuande/meetodi saamiseks tervishoiuasutusse viimase viie aasta jooksul (866). 
Vastusevariantides loetletud tervishoiuasutused olid: naistenõuandla, perearsti 
vastuvõtt (edaspidi perearstikeskus), naistearsti vastuvõtt erakliinikus (edaspidi 
erakliinik), noorte nõustamiskeskus ja muu. Uuringust langesid välja noorte 
nõustamiskeskuses ja mujal käinud vastajad ning need, kellel andmed tervis-
hoiuasutuse kohta puudusid. Rahulolu personali sõbralikkuse, asjatundlikkuse, 
usaldusväärsuse ja visiidi kestusega viimasel pöördumisel hindasid vastajad 
neljaastmelisel skaalal: väga rahul, pigem rahul, pigem rahulolematu, väga 
rahulolematu. Vastusevariantide alusel moodustati andmeanalüüsiks binaarne 
tunnus. Võimalikest rahulolu mõjutavatest taustateguritest vaatlesime hariduse, 
perekonnaseisu, majandusliku toimetuleku, elukoha ja tervise enesehinnangu 
seoseid rahulolu eri külgedega. Lisaks hindasime, kuivõrd tervishoiuasutus, 
kuhu pöörduti, osutus samaks, mida küsitletu oleks eelistanud, ning rahulolu 
seoseid külastatud tervishoiuasutusega. 
Paarisuhtevägivalla levimust küsitlusele eelneva 12 kuu jooksul ja selle seo-
seid eri seksuaaltervise aspektidega uurisime 16–44aastastel mitterasedatel 
seksuaalvahekorra kogemusega naistel (1966). Paarisuhtevägivalla toimepanijana 
a
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arvestasime ainult praegust või endist partnerit. Vägivalla hindamiseks kasu-
tasime seitsmest küsimusest koosnevat moodulit, milles olid üksikasjalikud 
küsimused vägivallaga ähvardamise, kehalise ja seksuaalse vägivalla eri ilmin-
gute kohta. Moodustasime sõltuva tunnusena kaks uuritavate rühma – ühed olid 
viimase 12 kuu jooksul kogenud füüsilise, seksuaalse või füüsilise ja seksuaalse 
vägivalla akte (362) ja teised mitte (1604). Analüüsisime neis rühmades kontrat-
septsioonimeetodite kasutamist viimases seksuaalvahekorras. Taustateguritest 
vaatlesime vanust, haridust, perekonnaseisu, rahvust, tegevusala, majanduslikku 
toimetulekut ja eelnevaid rasedusi. Erinevusi kahe rühma vahel hinnati hii ruut 
testi abil (P = 0,05). Näitajad kohandasime taustateguritele, mis statistiliselt 
usaldusväärselt erinesid rühmiti (vanus, haridus, majanduslik toimetulek, rahvus) 
neis mudelites, kus analüüsisime paarisuhtevägivalla seoseid kontratseptsiooni 
mittekasutamisega, ebatõhusate rasestumisvastaste meetodite kasutamisega, 
kordusabordiga, kondoomi kasutamisega elu jooksul, seksuaalsel teel levivatesse 
infektsioonidesse nakatumisega ja düspareuuniaga. 
Esitasime sõltumatute tunnuste kohta absoluut- ja suhtelised väärtused. Seo-
seid sõltuva tunnuse ja taustategurite vahel hindasime logistilise regressioon-
analüüsi abil. Riski hindamiseks arvutasime kohandamata ja taustateguritele 
kohandatud šansisuhte ning selle 95%lise usaldusvahemiku. Logistilise reg-
ressioonanalüüsi mudelis kohandasime šansisuhted valitud taustateguritele.  
Andmeanalüüsil kasutasime statistikapaketti Stata 10. 
 
TULEMUSED 
Indutseeritud abort (artikkel 1) 
Aastal 1996 oli Eestis 16 887 ja 2011 6 689 indutseeritud aborti, abortiivsus-
kordaja oli vastavalt 48,3 ja 20,7 ning abordimäär 128,7 ja 45. Sel perioodil 
langes abortiivsuskordaja 57,1% ja abordimäär 65,0%. Samal ajavahemikul 
tõusis sündimuse erikordaja 22,9%. Abortiivsuskordjad langesid kõigis vanuse-
rühmades, kuid enam 20–29aastaste hulgas, kus abortiivsuskordja oli ja on kõr-
geim. Kordusabordid moodustasid 63,8% (67 626) perioodil 1996–2003 ja 58% 
(38 132) perioodil 2004–2011. 26% moodustas teine abort mõlemal uuringu-
perioodil, kolmas vastavalt 17,2% ja 15,9% ja neljas või enam 20,6% ja 16,1%. 
Kordusabortide osakaal langes vaadeldud perioodidel kõigi sotsiaaldemograafi-
liste tunnuste lõikes, kuid oli kõige märgatavam alla 30aastastel, kõrgharidusega 
ja mittesünnitanud naistel. Muutus ei olnud statistiliselt usaldusväärne õppuritel 
ega alg- ja põhiharidusega naistel. Viimaste osakaal on kordusaborti teinute 
hulgas tõusnud. Kui 1996 aastal moodustasid vähema haridusega naised 7,7%, 
siis 2011. a 19,2% kõigist kordusaborti teinutest. Kuigi 20–29aastaste naiste 
osakaal oli rahvastikus perioodil 2004–2011 kõrgem, oli kordusabortide osakaal 
nende hulgas madalam võrreldes perioodiga 1996–2003. Kordusabortide osa-
kaal vähenes nii eestlaste kui mitte-eestlaste seas, kuid oli mitte-eestlastel suu-
rem nende hulgas, kes olid teinud kolm ja enam aborti. Mõlemal uuringu-
perioodil ei olnud üle poolte naistest vahetult enne aborti kasutanud rasestumis-
vastaseid meetodeid. 
 Kontratseptsioonimeetodite levimus ja seda mõjutavad tegurid Eestis ja 
Peterburis (artikkel II)  
Eri kontratseptsioonimeetodite levimus Eestis erines rahvuseti. Vastajatest, kes 
vajasid kaitset soovimatu raseduse eest, ei kasutanud üldse või kasutas eba-
tõhusaid meetodeid eesti emakeelega vastajatest 27,3%, vene emakeelega 
vastajatest 39,8% ja vastajatest Peterburis 42,5%. Tõhusate rasestumisvastaste 
meetodite kasutamises ilmnesid suured erinevused hormonaalsete meetodite 
(vastavalt 29,1%; 14,4% ja 11,0%) ja kondoomi korral (vastavalt 20,4%, 30,3% 
ja 41,3%). Viiendik Eesti vastajatest kasutas emakasisest meetodit, samal ajal 
Peterburis kasutas seda vaid 8,1%. Eesti emakeelega vastajad, kes olid 
vanemad, kel oli majanduslikke raskusi, kes suitsetasid ja kelle hulgas oli enam 
levinud seksuaalne riskikäitumine, kasutasid enam ebatõhusaid rasestumis-
vastaseid meetodeid või ei kasutanud neid üldse. Sellised seosed puudusid 
mitte-eestlastel. Eelnev sünnitus ja/või abort suurendasid oluliselt tõenäosust 
kasutada usaldusväärseid rasestumisvastaseid vahendeid eestlastel ja vastupidi, 
vähendasid seda Peterburis. Eestis vene emakeelega naistel vähendas tõenäosust 
kasutada tõhusate rasestumisvastaste meetodite kasutamist eelnev abort.  
 
Kontratseptsioonialane nõustamine Eestis (artikkel III) 
Rasestumisvastase nõuande/vahendi saamiseks pöördus viimase viie aasta jook-
sul tervishoiuasutustesse 61% kõigist 25–44aastastest vastanutest. 74% oli 
külastanud naistearsti naistenõuandlas, 17% naistearsti erakliinikus ja 9% pere-
arsti. 74% oli külastanud soovitud tervishoiuasutust. Enamik vastajaist (vähe-
malt 81%) olid rahul sõbralikkuse, asjatundlikkuse, usaldusväärsuse ja visiidi 
kestusega kõigis külastatud tervishoiuasutuses. Teenuse eri külgedega olid olu-
liselt enam rahul need, kes olid külastanud soovitud tervishoiuasutust, kes hin-
dasid oma tervist paremaks, väikelinnade ja maapiirkondade elanikud, eesti 
emakeelega vastajad. Perearsti ja erakliiniku külastajatel oli suurem šanss olla 
rahul visiidi kestusega (võrreldes naistenõuandlat külastanutega), erakliinikus 
ka personali usaldusväärsusega.  
 
Paarisuhte vägivalla levimus ja selle mõju reproduktiivsetele valikutele ja 
seksuaaltervisele (artikkel IV) 
Paarisuhtevägivalda oli uuringule eelnenud aasta jooksul kogenud 18,4% vasta-
jatest. Füüsilist vägivalda oli kogenud 17,2%, seksuaalset vägivalda 4,1% ja 
mõlemat 1,8%. Paarisuhtevägivalda kogenud vastajad olid oluliselt vähem 
kasutanud tõhusaid rasestumisvastaseid meetodeid viimases seksuaalvahekorras 
ning kondoomi elu jooksul; nad olid oluliselt enam katkestanud rasedusi, naka-
tunud seksuaalsel teel levivatesse infektsioonidesse ja kogenud düspareuuniat. 
 
Järeldused ja praktilised soovitused 
1. Viimase 16 aasta trendid näitavad märkimisväärset indutseeritud abortide 
langust ja aeglast, kuid püsivat kordusabortide langust, eriti nooremates 
vanuserühmades. Kordusabortide jätkuvalt kõrge tase on põhjustatud kõrgest 
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 abortiivsusest minevikus, olemasolevate trendide jätkudes võib ennustada 
peatset kordusabortide taseme kiiret langust. Kordusabortidest on enim ohus-
tatud madala haridustasemega, mitte-eestlastest ja sünnitanud naised. Pooled 
naised ei kasutanud enne aborti mingit rasestumisvastast meetodit. Kõik 
meetmed, mis vähendavad soovimatuid rasedusi ja hoiavad ära esmasabordi, 
vähendavad ka kordusabordi vajadust. Abordi korral peab kontratseptsiooni-
alane nõustamine muutuma enesestmõistetavaks teenuse osaks. Kontratsept-
siooni kasutamist peab alustama kohe pärast aborti eelistades pikaajalisi 
taaspöörduvaid rasestumisvastaseid meetodeid.  
2. Katmata vajadusi naiste reproduktiivsetes valikutes peegeldab asjaolu, et 
kolmandik naistest, kes vajavad kaitset soovimatu raseduse eest, kasutasid 
ebatõhusaid rasestumisvastaseid meetodeid või kasutanud neid üldse. Ilmne-
sid olulised erinevused eestlaste ja mitte-eestlaste vahel nii kontratsept-
sioonimeetodite levimuses kui nende kasutamisega seotud tegurites. Selgelt 
on olemas vajadus edastada tõenduspõhist infot kaasaaegse tõhusa kontrat-
septsiooni kohta ja pöörama rohkem tähelepanu Eesti venekeelsele kogu-
konnale. 
3. Üle 24aastased naised said ja eelistasid saada kontratseptsioonialast nõu 
naistearstilt naistenõuandas või erakliinikus. Esmatasandi roll oli tagasi-
hoidlik. Vähemalt 81% vastajatest oli rahul sõbralikkuse, asjatundlikkuse, 
usaldusväärsuse ja visiidi kestusega kõigis külastatud tervishoiuasutuses. Et 
parandada kontratseptsioonialase nõu kättesaadavust, peab edendama esma-
tasandi arstiabi rolli nõustamise pakkujana. 
4. Paarisuhtevägivald on Eestis väga levinud – iga viies naine kannatas 
füüsilise või seksuaalvägivalla all uuringule eelnenud 12 kuu jooksul. Paari-
suhtevägivalla kogemus oli oluliselt seotud seksuaaltervise riskidega. Sek-
suaaltervise edendamiseks ja parandamiseks kasutatavad strateegiad Eestis 
peavad sisaldama naistevastase vägivalla, sh paarisuhtevägivalla ennetamist, 
et paremini kaitsta naiste seksuaalseid õigusi. Kiire vajadus on paarisuhte- ja 
seksuaalvägivalla strateegia ning käsitlusjuhendi väljatöötamiseks Eesti 
tervishoiusüsteemis. 
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